ISAF Anti-Doping Code

Regulation 21

A submission from the Executive Committee

Purpose or Objective

The World Anti-Doping Code is the core document that provides the framework for harmonized anti-doping policies, rules and regulations within sports organizations and among public authorities. Building on experience gained in the application of the Code, and following an extensive consultation process with all stakeholders, the new Code was adopted in November 2013.

Proposal

Delete Current regulation 21 and replace with:

21. ANTI-DOPING CODE

INTRODUCTION

Preface

These Anti-Doping Rules are adopted and implemented in accordance with the International Sailing Federation (ISAF)'s responsibilities under the Code, and in furtherance of ISAF's continuing efforts to eradicate doping in sport.

These Anti-Doping Rules are sport rules governing the conditions under which sport is played. Aimed at enforcing anti-doping principles in a global and harmonized manner, they are distinct in nature from criminal and civil laws, and are not intended to be subject to or limited by any national requirements and legal standards applicable to criminal or civil proceedings. When reviewing the facts and the law of a given case, all courts, arbitral tribunals and other adjudicating bodies should be aware of and respect the distinct nature of these Anti-Doping Rules implementing the Code and the fact that these rules represent the consensus of a broad spectrum of stakeholders around the world as to what is necessary to protect and ensure fair sport.

Fundamental Rationale for the Code and ISAF's Anti-Doping Rules

Anti-doping programs seek to preserve what is intrinsically valuable about sport. This intrinsic value is often referred to as "the spirit of sport". It is the essence of Olympism, the pursuit of human excellence through the dedicated perfection of each person's natural talents. It is how we play true. The spirit of sport is the celebration of the human spirit, body and mind, and is reflected in values we find in and through sport, including:

- Ethics, fair play and honesty
- Health
• Excellence in performance
• Character and education
• Fun and joy
• Teamwork
• Dedication and commitment
• Respect for rules and laws
• Respect for self and other Participants
• Courage
• Community and solidarity

Doping is fundamentally contrary to the spirit of sport.

Scope of these Anti-Doping Rules

These Anti-Doping Rules shall apply to ISAF and to each of its Member National Authorities (MNAs). They also apply to the following Athletes, Athlete Support Personnel and other Persons, each of whom is deemed, as a condition of his/her membership, accreditation and/or participation in the sport, to have agreed to be bound by these Anti-Doping Rules, and to have submitted to the authority of ISAF to enforce these Anti-Doping Rules and to the jurisdiction of the hearing panels specified in Regulation 8 and Regulation 13 to hear and determine cases and appeals brought under these Anti-Doping Rules:

a. all Athletes and Athlete Support Personnel who are members of ISAF, or of any MNA, or of any member or affiliate organization of any MNA (including any clubs, teams, associations or leagues);

b. all Athletes and Athlete Support Personnel participating in such capacity in Events, Competitions and other activities organized, convened, authorized or recognized by ISAF, or any MNA, or any member or affiliate organization of any MNA (including any clubs, teams, associations or leagues), wherever held;

c. any other Athlete or Athlete Support Personnel or other Person who, by virtue of an accreditation, a licence or other contractual arrangement, or otherwise, is subject to the jurisdiction of ISAF, or of any MNA, or of any member or affiliate organization of any MNA (including any clubs, teams, associations or leagues), for purposes of anti-doping; and

d. Athletes who are not regular members of ISAF or of one of its MNAs but who want to be eligible to compete in a particular International Event. ISAF may include such Athletes in its Registered Testing Pool so that they are required to provide information about their whereabouts for purposes of Testing under these Anti-Doping Rules for at least one month prior to the International Event in question.

Within the overall pool of Athletes set out above who are bound by and required to comply with these Anti-Doping Rules, the following Athletes shall be considered to be International-Level Athletes for purposes of these Anti-Doping Rules, and therefore the specific provisions in these Anti-Doping Rules applicable to International-Level Athletes (as regards Testing but also as regards TUEs, whereabouts information, results management, and appeals) shall apply to such Athletes:

c. Athletes who compete in any of the following International Events:
ISAF Sailing World Cup
ISAF Sailing World Championship
ISAF Youth Sailing World Championships
IFDS Combined World Championship
Olympic Games
Paralympic Games

And any other events that ISAF adds to the recognized International Events on the ISAF Anti-Doping microsite found at www.sailing.org.

DEFINITIONS

ADAMS: The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and WADA in their anti-doping operations in conjunction with data protection legislation.

Administration: Providing, supplying, supervising, facilitating, or otherwise participating in the Use or Attempted Use by another Person of a Prohibited Substance or Prohibited Method. However, this definition shall not include the actions of bona fide medical personnel involving a Prohibited Substance or Prohibited Method used for genuine and legal therapeutic purposes or other acceptable justification and shall not include actions involving Prohibited Substances which are not prohibited in Out-of-Competition Testing unless the circumstances as a whole demonstrate that such Prohibited Substances are not intended for genuine and legal therapeutic purposes or are intended to enhance sport performance.

Adverse Analytical Finding: A report from a WADA-accredited laboratory or other WADA-approved laboratory that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the Use of a Prohibited Method.

Adverse Passport Finding: A report identified as an Adverse Passport Finding as described in the applicable International Standards.

Anti-Doping Organization: A Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, WADA, International Federations, and National Anti-Doping Organizations.

Athlete: Any Person who competes in sport at the international level (as defined by each International Federation), or the national level (as defined by each National Anti-Doping Organization). An Anti-Doping Organization has discretion to apply anti-doping rules to an Athlete who is neither an International-Level Athlete nor a National-Level Athlete, and thus to bring them within the definition of “Athlete.” In relation to Athletes who are neither International-Level nor National-Level Athletes, an Anti-Doping Organization may elect to: conduct limited Testing or no Testing at all; analyze Samples for less than the full menu of Prohibited Substances; require limited or no whereabouts information; or not require advance TUEs. However, if an Regulation 21.2.1, 21.2.3 or 21.2.5 anti-doping rule
violation is committed by any Athlete over whom an Anti-Doping Organization has authority who competes below the international or national level, then the Consequences set forth in the Code (except Regulation 21.14.3(b)) must be applied. For purposes of Regulation 21.2.8 and Regulation 21.2.9 and for purposes of anti-doping information and education, any Person who participates in sport under the authority of any Signatory, government, or other sports organization accepting the Code is an Athlete.

**Athlete Biological Passport:** The program and methods of gathering and collating data as described in the International Standard for Testing and Investigations and International Standard for Laboratories.

**Athlete Support Personnel:** Any coach, trainer, manager, agent, team staff, official, medical, paramedical personnel, parent or any other Person working with, treating or assisting an Athlete participating in or preparing for sports Competition.

**Attempt:** Purposely engaging in conduct that constitutes a substantial step in a course of conduct planned to culminate in the commission of an anti-doping rule violation. Provided, however, there shall be no anti-doping rule violation based solely on an Attempt to commit a violation if the Person renounces the Attempt prior to it being discovered by a third party not involved in the Attempt.

**Atypical Finding:** A report from a WADA-accredited laboratory or other WADA-approved laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Adverse Analytical Finding.

**Atypical Passport Finding:** A report described as an Atypical Passport Finding as described in the applicable International Standards.

**CAS:** The Court of Arbitration for Sport.

**Code:** The World Anti-Doping Code.

**Competition:** A single race, match, game or singular sport contest. For example, a basketball game or the finals of the Olympic 100-meter race in athletics. For stage races and other sport contests where prizes are awarded on a daily or other interim basis the distinction between a Competition and an Event will be as provided in the rules of the applicable International Federation.

**Consequences of Anti-Doping Rule Violations (“Consequences”):** An Athlete’s or other Person’s violation of an anti-doping rule may result in one or more of the following: (a) **Disqualification** means the Athlete’s results in a particular Competition or Event are invalidated, with all resulting Consequences including forfeiture of any medals, points and prizes; (b) **Ineligibility** means the Athlete or other Person is barred on account of an anti-doping rule violation for a specified period of time from participating in any Competition or other activity or funding as provided in Regulation 21.10.12(a); (c) **Provisional Suspension** means the Athlete or other Person is barred temporarily from participating in any Competition or activity prior to the final decision at a hearing conducted under Regulation 21.8; (d) **Financial Consequences** means a financial sanction imposed for an anti-doping rule violation or to recover costs associated with an anti-doping rule violation; and (e) **Public Disclosure or Public Reporting** means the dissemination or distribution of information to the general public or Persons beyond those Persons entitled to earlier notification in accordance with Regulation 21.14. Teams in Team Sports may also be subject to Consequences as provided in Article 11 of the Code.
**Contaminated Product**: A product that contains a *Prohibited Substance* that is not disclosed on the product label or in information available in a reasonable Internet search.

**Disqualification**: See *Consequences of Anti-Doping Rule Violations* above.

**Doping Control**: All steps and processes from test distribution planning through to ultimate disposition of any appeal including all steps and processes in between such as provision of whereabouts information, *Sample* collection and handling, laboratory analysis, *TUEs*, results management and hearings.

**Event**: A series of individual *Competitions* conducted together under one ruling body (e.g., the Olympic Games, FINA World Championships, or Pan American Games).

**Event Venues**: Those venues so designated by the ruling body for the *Event*.

**Event Period**: The time between the beginning and end of an *Event*, as established by the ruling body of the *Event*.

**Fault**: *Fault* is any breach of duty or any lack of care appropriate to a particular situation. Factors to be taken into consideration in assessing an *Athlete* or other *Person’s* degree of *Fault* include, for example, the *Athlete’s* or other *Person’s* experience, whether the *Athlete* or other *Person* is a *Minor*, special considerations such as impairment, the degree of risk that should have been perceived by the *Athlete* and the level of care and investigation exercised by the *Athlete* in relation to what should have been the perceived level of risk. In assessing the *Athlete’s* or other *Person’s* degree of *Fault*, the circumstances considered must be specific and relevant to explain the *Athlete’s* or other *Person’s* departure from the expected standard of behavior. Thus, for example, the fact that an *Athlete* would lose the opportunity to earn large sums of money during a period of *Ineligibility*, or the fact that the *Athlete* only has a short time left in his or her career, or the timing of the sporting calendar, would not be relevant factors to be considered in reducing the period of *Ineligibility* under Regulation 21.10.5(a) or 21.10.5(b).

**Financial Consequences**: see *Consequences of Anti-Doping Rule Violations*, above.

**In-Competition**: For purposes of differentiating between *In-Competition* and *Out-of-Competition Testing*, for *Events* for which ISAF is the ruling body, *In-Competition* is defined as that period of time between the scheduled time of the warning signal of the first race of the *Event*, until to the protest time limit following the final race of the *Event*.

**Independent Observer Program**: A team of observers, under the supervision of WADA, who observe and provide guidance on the *Doping Control* process at certain *Events* and report on their observations.

**Individual Sport**: Any sport that is not a *Team Sport*.

**Ineligibility**: See *Consequences of Anti-Doping Rule Violations* above.

**International Event**: An *Event* or *Competition* where the International Olympic Committee, the International Paralympic Committee, an International Federation, a *Major Event Organization*, or another international sport organization is the ruling body for the *Event* or appoints the technical officials for the *Event*. 
International-Level Athlete: Athletes who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations. For the sport of Sailing, International-Level Athletes are defined as set out in the Scope section of the Introduction to these Anti-Doping Rules.

International Standard: A standard adopted by WADA in support of the Code. Compliance with an International Standard (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the International Standard were performed properly. International Standards shall include any Technical Documents issued pursuant to the International Standard.

Major Event Organizations: The continental associations of National Olympic Committees and other international multi-sport organizations that function as the ruling body for any continental, regional or other International Event.

Marker: A compound, group of compounds or biological variable(s) that indicates the Use of a Prohibited Substance or Prohibited Method.

Metabolite: Any substance produced by a biotransformation process.

Minor: A natural Person who has not reached the age of eighteen years.

National Anti-Doping Organization: The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of Samples, the management of test results, and the conduct of hearings at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country’s National Olympic Committee or its designee.

National Event: A sport Event or Competition involving International- or National-Level Athletes that is not an International Event.

MNA: A national or regional entity which is a member of or is recognized by ISAF as the entity governing ISAF's sport in that nation or region. A Relevant MNA means the MNA designated by ISAF as having jurisdiction over the Athlete or other Person in question. MNAs have the duties and responsibilities of National Federations under the Code.

National-Level Athlete: Athletes who compete in sport at the national level, as defined by each National Anti-Doping Organization, consistent with the International Standard for Testing and Investigations.

National Olympic Committee: The organization recognized by the International Olympic Committee. The term National Olympic Committee shall also include the National Sport Confederation in those countries where the National Sport Confederation assumes typical National Olympic Committee responsibilities in the anti-doping area.

No Fault or Negligence: The Athlete or other Person’s establishing that he or she did not know or suspect, and could not reasonably have known or suspected even with the exercise of utmost caution, that he or she had Used or been administered the Prohibited Substance or Prohibited Method or
otherwise violated an anti-doping rule. Except in the case of a Minor, for any violation of Regulation 21.2.1, the Athlete must also establish how the Prohibited Substance entered his or her system.

No Significant Fault or Negligence: The Athlete or other Person’s establishing that his or her Fault or negligence, when viewed in the totality of the circumstances and taking into account the criteria for No Fault or negligence, was not significant in relationship to the anti-doping rule violation. Except in the case of a Minor, for any violation of Regulation 21.2.1, the Athlete must also establish how the Prohibited Substance entered his or her system.

Out-of-Competition: Any period which is not In-Competition.

Participant: Any Athlete or Athlete Support Person.

Person: A natural Person or an organization or other entity.

Possession: The actual, physical Possession, or the constructive Possession (which shall be found only if the Person has exclusive control or intends to exercise control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists); provided, however, that if the Person does not have exclusive control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists, constructive Possession shall only be found if the Person knew about the presence of the Prohibited Substance or Prohibited Method and intended to exercise control over it. Provided, however, there shall be no anti-doping rule violation based solely on Possession if, prior to receiving notification of any kind that the Person has committed an anti-doping rule violation, the Person has taken concrete action demonstrating that the Person never intended to have Possession and has renounced Possession by explicitly declaring it to an Anti-Doping Organization. Notwithstanding anything to the contrary in this definition, the purchase (including by any electronic or other means) of a Prohibited Substance or Prohibited Method constitutes Possession by the Person who makes the purchase.

Prohibited List: The List identifying the Prohibited Substances and Prohibited Methods.

Prohibited Method: Any method so described on the Prohibited List.

Prohibited Substance: Any substance, or class of substances, so described on the Prohibited List.

Provisional Hearing: For purposes of Regulation 21.7.9, an expedited abbreviated hearing occurring prior to a hearing under Regulation 21.8 that provides the Athlete with notice and an opportunity to be heard in either written or oral form.

Provisional Suspension: See Consequences of Anti-Doping Rule Violations above.

Publicly Disclose or Publicly Report: See Consequences of Anti-Doping Rule Violations above.

Regional Anti-Doping Organization: A regional entity designated by member countries to coordinate and manage delegated areas of their national anti-doping programs, which may include the adoption and implementation of anti-doping rules, the planning and collection of Samples, the management of results, the review of TUEs, the conduct of hearings, and the conduct of educational programs at a regional level.
**Registered Testing Pool**: The pool of highest-priority Athletes established separately at the international level by International Federations and at the national level by National Anti-Doping Organizations, who are subject to focused In-Competition and Out-of-Competition Testing as part of that International Federation's or National Anti-Doping Organization's test distribution plan and therefore are required to provide whereabouts information as provided in Article 5.6 of the Code and the International Standard for Testing and Investigations.

**Sample or Specimen**: Any biological material collected for the purposes of Doping Control.

**Signatories**: Those entities signing the Code and agreeing to comply with the Code, as provided in Article 23 of the Code.

**Specified Substance**: See Regulation 21.4.2(b).

**Strict Liability**: The rule which provides that under Regulation 21.2.1 and Regulation 21.2.2, it is not necessary that intent, Fault, negligence, or knowing Use on the Athlete’s part be demonstrated by the Anti-Doping Organization in order to establish an anti-doping rule violation.

**Substantial Assistance**: For purposes of Regulation 21.10.6(a), a Person providing Substantial Assistance must: (1) fully disclose in a signed written statement all information he or she possesses in relation to anti-doping rule violations, and (2) fully cooperate with the investigation and adjudication of any case related to that information, including, for example, presenting testimony at a hearing if requested to do so by an Anti-Doping Organization or hearing panel. Further, the information provided must be credible and must comprise an important part of any case which is initiated or, if no case is initiated, must have provided a sufficient basis on which a case could have been brought.

**Tampering**: Altering for an improper purpose or in an improper way; bringing improper influence to bear; interfering improperly; obstructing, misleading or engaging in any fraudulent conduct to alter results or prevent normal procedures from occurring.


**Team Sport**: A sport in which the substitution of players is permitted during a Competition.

**Testing**: The parts of the Doping Control process involving test distribution planning, Sample collection, Sample handling, and Sample transport to the laboratory.

**Trafficking**: Selling, giving, transporting, sending, delivering or distributing (or Possessing for any such purpose) a Prohibited Substance or Prohibited Method (either physically or by any electronic or other means) by an Athlete, Athlete Support Person or any other Person subject to the jurisdiction of an Anti-Doping Organization to any third party; provided, however, this definition shall not include the actions of “bona fide” medical personnel involving a Prohibited Substance used for genuine and legal therapeutic purposes or other acceptable justification, and shall not include actions involving Prohibited Substances which are not prohibited in Out-of-Competition Testing unless the circumstances as a whole demonstrate such Prohibited Substances are not intended for genuine and legal therapeutic purposes or are intended to enhance sport performance.

**TUE**: Therapeutic Use Exemption, as described in Regulation 21.4.4.
**TUE Committee**: A Committee of the ISAF Medical Commission responsible for evaluating requests for TUEs, as described in Regulation 21.4.

**UNESCO Convention**: The International Convention against Doping in Sport adopted by the 33rd session of the UNESCO General Conference on 19 October, 2005 including any and all amendments adopted by the States Parties to the Convention and the Conference of Parties to the International Convention against Doping in Sport.

**Use**: The utilization, application, ingestion, injection or consumption by any means whatsoever of any Prohibited Substance or Prohibited Method.

**WADA**: The World Anti-Doping Agency.

**Definition of Doping**

21.1 Doping is defined as the occurrence of one or more of the anti-doping rule violations set forth in Regulation 21.2.1 through Regulation 21.10 of these Anti-Doping Rules.

**Anti-Doping Rule Violations**

21.2 The purpose of Regulation 21.2 is to specify the circumstances and conduct which constitute anti-doping rule violations. Hearings in doping cases will proceed based on the assertion that one or more of these specific rules have been violated.

*Athletes* or other *Persons* shall be responsible for knowing what constitutes an anti-doping rule violation and the substances and methods which have been included on the *Prohibited List*.

The following constitute anti-doping rule violations:

**21.2.1 Presence of a Prohibited Substance or its Metabolites or Markers in an Athlete’s Sample**

(a) It is each *Athlete’s* personal duty to ensure that no *Prohibited Substance* enters his or her body. *Athletes* are responsible for any *Prohibited Substance* or its *Metabolites* or *Markers* found to be present in their *Samples*. Accordingly, it is not necessary that intent, *Fault*, negligence or knowing *Use* on the *Athlete’s* part be demonstrated in order to establish an anti-doping rule violation under Regulation 2.1.

(b) Sufficient proof of an anti-doping rule violation under Regulation 2.1 is established by any of the following: presence of a *Prohibited Substance* or its *Metabolites* or *Markers* in the *Athlete’s A Sample* where the *Athlete* waives analysis of the *B Sample* and the *B Sample* is not analyzed; or, where the *Athlete’s B Sample* is analyzed and the analysis of the *Athlete’s B Sample* confirms the presence of the *Prohibited Substance* or its *Metabolites* or *Markers* found in the *Athlete’s A Sample*; or, where the *Athlete’s B Sample* is split into two
bottles and the analysis of the second bottle confirms the presence of the Prohibited Substance or its Metabolites or Markers found in the first bottle.

(c) Excepting those substances for which a quantitative threshold is specifically identified in the Prohibited List, the presence of any quantity of a Prohibited Substance or its Metabolites or Markers in an Athlete’s Sample shall constitute an anti-doping rule violation.

(d) As an exception to the general rule of Regulation 2.1, the Prohibited List or International Standards may establish special criteria for the evaluation of Prohibited Substances that can also be produced endogenously.

21.2.2 Use or Attempted Use by an Athlete of a Prohibited Substance or a Prohibited Method

(a) It is each Athlete’s personal duty to ensure that no Prohibited Substance enters his or her body and that no Prohibited Method is Used. Accordingly, it is not necessary that intent, fault, negligence or knowing use on the Athlete’s part be demonstrated in order to establish an anti-doping rule violation for Use of a Prohibited Substance or a Prohibited Method.

(b) The success or failure of the Use or Attempted Use of a Prohibited Substance or Prohibited Method is not material. It is sufficient that the Prohibited Substance or Prohibited Method was Used or Attempted to be Used for an anti-doping rule violation to be committed.

21.2.3 Evading, Refusing or Failing to Submit to Sample Collection

Evading Sample collection, or without compelling justification refusing or failing to submit to Sample collection after notification as authorized in these Anti-Doping Rules or other applicable anti-doping rules.

21.2.4 Whereabouts Failures

Any combination of three missed tests and/or filing failures, as defined in the International Standard for Testing and Investigations, within a twelve-month period by an Athlete in a Registered Testing Pool.

21.2.5 Tampering or Attempted Tampering with any part of Doping Control

Conduct which subverts the Doping Control process but which would not otherwise be included in the definition of Prohibited Methods. Tampering shall include, without limitation, intentionally interfering or attempting to interfere with a Doping Control official, providing fraudulent information to an Anti-Doping Organization, or intimidating or attempting to intimidate a potential witness.

21.2.6 Possession of a Prohibited Substance or a Prohibited Method
(a) Possession by an Athlete In-Competition of any Prohibited Substance or any Prohibited Method, or Possession by an Athlete Out-of-Competition of any Prohibited Substance or any Prohibited Method which is prohibited Out-of-Competition unless the Athlete establishes that the Possession is consistent with a Therapeutic Use Exemption (“TUE”) granted in accordance with Regulation 21.4.4 or other acceptable justification.

(b) Possession by an Athlete Support Person In-Competition of any Prohibited Substance or any Prohibited Method, or Possession by an Athlete Support Person Out-of-Competition of any Prohibited Substance or any Prohibited Method which is prohibited Out-of-Competition in connection with an Athlete, Competition or training, unless the Athlete Support Person establishes that the Possession is consistent with a TUE granted to an Athlete in accordance with Regulation 21.4.4 or other acceptable justification.

21.2.7 Trafficking or Attempted Trafficking in any Prohibited Substance or Prohibited Method

21.2.8 Administration or Attempted Administration to any Athlete In-Competition of any Prohibited Substance or Prohibited Method, or Administration or Attempted Administration to any Athlete Out-of-Competition of any Prohibited Substance or any Method that is prohibited Out-of-Competition

21.2.9 Complicity

Assisting, encouraging, aiding, abetting, conspiring, covering up or any other type of intentional complicity involving an anti-doping rule violation, Attempted anti-doping rule violation or violation of Regulation 21.10.12(a) by another Person.

21.2.10 Prohibited Association

Association by an Athlete or other Person subject to the authority of an Anti-Doping Organization in a professional or sport-related capacity with any Athlete Support Person who:

(a) If subject to the authority of an Anti-Doping Organization, is serving a period of Ineligibility; or

(b) If not subject to the authority of an Anti-Doping Organization and where Ineligibility has not been addressed in a results management process pursuant to the Code, has been convicted or found in a criminal, disciplinary or professional proceeding to have engaged in conduct which would have constituted a violation of anti-doping rules if Code-compliant rules had been applicable to such Person. The disqualifying status of such Person shall be in force for the longer of six years from the criminal, professional or disciplinary decision or the duration of the criminal, disciplinary or professional sanction imposed; or

(c) Is serving as a front or intermediary for an individual described in Regulation 21.2.10(a) or 21.2.10(b).
In order for this provision to apply, it is necessary that the Athlete or other Person has previously been advised in writing by an Anti-Doping Organization with jurisdiction over the Athlete or other Person, or by WADA, of the Athlete Support Person’s disqualifying status and the potential Consequence of prohibited association and that the Athlete or other Person can reasonably avoid the association. The Anti-Doping Organization shall also use reasonable efforts to advise the Athlete Support Person who is the subject of the notice to the Athlete or other Person that the Athlete Support Person may, within 15 days, come forward to the Anti-Doping Organization to explain that the criteria described in Regulations 21.2.10(a) and 21.2.10(b) do not apply to him or her. (Notwithstanding Regulation 21.17, this Regulation applies even when the Athlete Support Person’s disqualifying conduct occurred prior to the effective date provided in Regulation 21.20.7.)

The burden shall be on the Athlete or other Person to establish that any association with Athlete Support Personnel described in Regulation 21.2.10(a) or 21.2.10(b) is not in a professional or sport-related capacity.

Anti-Doping Organizations that are aware of Athlete Support Personnel who meet the criteria described in Regulation 21.2.10(a), 21.2.10(b), or 21.2.10(c) shall submit that information to WADA.

21.3 Proof of Doping

21.3.1 Burdens and Standards of Proof

ISAF and its MNAs shall have the burden of establishing that an anti-doping rule violation has occurred. The standard of proof shall be whether ISAF has established an anti-doping rule violation to the comfortable satisfaction of the hearing panel bearing in mind the seriousness of the allegation which is made. This standard of proof in all cases is greater than a mere balance of probability but less than proof beyond a reasonable doubt. Where these Anti-Doping Rules place the burden of proof upon the Athlete or other Person alleged to have committed an anti-doping rule violation to rebut a presumption or establish specified facts or circumstances, the standard of proof shall be by a balance of probability.

21.3.2 Methods of Establishing Facts and Presumptions

Facts related to anti-doping rule violations may be established by any reliable means, including admissions. The following rules of proof shall be applicable in doping cases:

(a) Analytical methods or decision limits approved by WADA after consultation within relevant scientific community and which have been the subject of peer review are presumed to be scientifically valid. Any Athlete or other Person seeking to rebut this presumption of scientific validity shall, as a condition precedent to any such challenge, first notify WADA of the challenge and the basis of the challenge. CAS on its own initiative may also inform WADA of any such challenge. At WADA’s request, the CAS panel shall appoint an appropriate scientific expert to assist the panel in its evaluation of the challenge. Within 10 days of WADA’s receipt of such notice, and WADA’s receipt of the CAS file, WADA shall also have the right to intervene as a party, appear amicus curiae, or otherwise provide evidence in such proceeding.
(b) WADA-accredited laboratories, and other laboratories approved by WADA, are presumed to have conducted Sample analysis and custodial procedures in accordance with the International Standard for Laboratories. The Athlete or other Person may rebut this presumption by establishing that a departure from the International Standard for Laboratories occurred which could reasonably have caused the Adverse Analytical Finding. If the Athlete or other Person rebuts the preceding presumption by showing that a departure from the International Standard for Laboratories occurred which could reasonably have caused the Adverse Analytical Finding, then ISAF shall have the burden to establish that such departure did not cause the Adverse Analytical Finding.

(c) Departures from any other International Standard or other anti-doping rule or policy set forth in the Code or these Anti-Doping Rules which did not cause an Adverse Analytical Finding or other anti-doping rule violation shall not invalidate such evidence or results. If the Athlete or other Person establishes a departure from another International Standard or other anti-doping rule or policy which could reasonably have caused an anti-doping rule violation based on an Adverse Analytical Finding or other anti-doping rule violation, then ISAF shall have the burden to establish that such departure did not cause the Adverse Analytical Finding or the factual basis for the anti-doping rule violation.

(d) The facts established by a decision of a court or professional disciplinary tribunal of competent jurisdiction which is not the subject of a pending appeal shall be irrebuttable evidence against the Athlete or other Person to whom the decision pertained of those facts unless the Athlete or other Person establishes that the decision violated principles of natural justice.

(e) The hearing panel in a hearing on an anti-doping rule violation may draw an inference adverse to the Athlete or other Person who is asserted to have committed an anti-doping rule violation based on the Athlete’s or other Person’s refusal, after a request made in a reasonable time in advance of the hearing, to appear at the hearing (either in person or telephonically as directed by the hearing panel) and to answer questions from the hearing panel or ISAF.

21.4 The Prohibited List

21.4.1 Incorporation of the Prohibited List

These Anti-Doping Rules incorporate the Prohibited List, which is published and revised by WADA as described in Article 4.1 of the Code.

21.4.2 Prohibited Substances and Prohibited Methods Identified on the Prohibited List

(a) Prohibited Substances and Prohibited Methods

Unless provided otherwise in the Prohibited List and/or a revision, the Prohibited List and revisions shall go into effect under these Anti-Doping Rules three months after publication by WADA, without requiring any further action by ISAF or its MNAs. All Athletes and other Persons shall be bound by the Prohibited List, and any revisions
thereto, from the date they go into effect, without further formality. It is the responsibility of all Athletes and other Persons to familiarize themselves with the most up-to-date version of the Prohibited List and all revisions thereto.

(b) Specified Substances

For purposes of the application of Regulation 21.10, all Prohibited Substances shall be Specified Substances except substances in the classes of anabolic agents and hormones and those stimulants and hormone antagonists and modulators so identified on the Prohibited List. The category of Specified Substances shall not include Prohibited Methods.

21.4.3 WADA’s Determination of the Prohibited List

WADA’s determination of the Prohibited Substances and Prohibited Methods that will be included on the Prohibited List, the classification of substances into categories on the Prohibited List, and the classification of a substance as prohibited at all times or In-Competition only, is final and shall not be subject to challenge by an Athlete or other Person based on an argument that the substance or method was not a masking agent or did not have the potential to enhance performance, represent a health risk or violate the spirit of sport.

21.4.4 Therapeutic Use Exemptions (“TUEs”)

(a) The presence of a Prohibited Substance or its Metabolites or Markers, and/or the Use or Attempted Use, Possession or Administration or Attempted Administration of a Prohibited Substance or Prohibited Method, shall not be considered an anti-doping rule violation if it is consistent with the provisions of a TUE granted in accordance with the International Standard for Therapeutic Use Exemptions.

(b) If an International-Level Athlete is using a Prohibited Substance or a Prohibited Method for therapeutic reasons:

(i) Where the Athlete already has a TUE granted by his or her National Anti-Doping Organization for the substance or method in question, that TUE is not automatically valid for international-level Competition. However, the Athlete may apply to ISAF to recognize that TUE, in accordance with Article 7 of the International Standard for Therapeutic Use Exemptions. If that TUE meets the criteria set out in the International Standard for Therapeutic Use Exemptions, then ISAF shall recognize it for purposes of international-level Competition as well. If ISAF considers that the TUE does not meet those criteria and so refuses to recognize it, ISAF shall notify the Athlete and his or her National Anti-Doping Organization promptly, with reasons. The Athlete and the National Anti-Doping Organization shall have 21 days from such notification to refer the matter to WADA for review in accordance with Regulation 21.4.4(f). If the matter is referred to WADA for review, the TUE granted by the National Anti-Doping Organization remains valid for national-level Competition and Out-of-Competition Testing (but is not valid for international-level Competition) pending WADA’s decision. If the matter is not referred to WADA for review, the TUE becomes invalid for any purpose when the 21-day review deadline expires.
(ii) If the Athlete does not already have a TUE granted by his/her National Anti-Doping Organization for the substance or method in question, the Athlete must apply directly to ISAF for a TUE in accordance with the process set out in the International Standard for Therapeutic Use Exemptions, using the form posted on ISAF’s website at http://www.sailing.org/sailors/antidoping/documents.php. If ISAF denies the Athlete’s application, it must notify the Athlete promptly, with reasons. If ISAF grants the Athlete’s application, it shall notify not only the Athlete but also his/her National Anti-Doping Organization. If the National Anti-Doping Organization considers that the TUE granted by ISAF does not meet the criteria set out in the International Standard for Therapeutic Use Exemptions, it has 21 days from such notification to refer the matter to WADA for review in accordance with Regulation 21.4.4(f). If the National Anti-Doping Organization refers the matter to WADA for review, the TUE granted by ISAF remains valid for international-level Competition and Out-of-Competition Testing (but is not valid for national-level Competition) pending WADA’s decision. If the National Anti-Doping Organization does not refer the matter to WADA for review, the TUE granted by ISAF becomes valid for national-level Competition as well when the 21-day review deadline expires.

(c) If ISAF chooses to test an Athlete who is not an International-Level Athlete, ISAF shall recognize a TUE granted to that Athlete by his or her National Anti-Doping Organization. If ISAF chooses to test an Athlete who is not an International-Level or a National-Level Athlete, ISAF shall permit that Athlete to apply for a retroactive TUE for any Prohibited Substance or Prohibited Method that he/she is using for therapeutic reasons.

(d) An application to ISAF for grant or recognition of a TUE must be made as soon as the need arises and in any event (save in emergency or exceptional situations or where Article 4.3 of the International Standard for Therapeutic Use Exemptions applies) at least 30 days before the Athlete’s next Competition. ISAF shall appoint a panel to consider applications for the grant or recognition of TUEs (the “TUE Committee”). The TUE Committee shall promptly evaluate and decide upon the application in accordance with the relevant provisions of the International Standard for Therapeutic Use Exemptions. Its decision shall be the final decision of ISAF, and shall be reported to WADA and other relevant Anti-Doping Organizations, including the Athlete’s National Anti-Doping Organization, through ADAMS, in accordance with the International Standard for Therapeutic Use Exemptions.

(i) In offshore races of more than 50 nautical miles, the use of any Prohibited Substance or Prohibited Methods for emergency medical treatment shall be recorded. The TUE Committee may approve such Use and Possession of such medications as reasonably required if the acute situation or exceptional circumstances are confirmed to the satisfaction of the TUE Committee.
(ii) If any Prohibited Substances carried on board are used, an explanation satisfactory to the TUE Committee will need to be provided and the process for consideration of retroactive approval of a TUE will take place.

(iii) With the approval of the ISAF or a Member National Authority or National Olympic Committee (NOC), a Team Doctor or a Doctor who is responsible for sailing competitors, officials and others in the care of that Doctor, may carry and employ such medications as the circumstances may require and as might be properly used in the undertaking of the Hippocratic oath. The TUE Committee may retroactively approve such Use.

(e) Expiration, Cancellation, Withdrawal or Reversal of a TUE

(i) A TUE granted pursuant to these Anti-Doping Rules: (a) shall expire automatically at the end of any term for which it was granted, without the for any further notice or other formality; (b) may be cancelled if the Athlete does not promptly comply with any requirements or conditions imposed by the TUE Committee upon grant of the TUE; (c) may be withdrawn by the TUE Committee if it is subsequently determined that the criteria for grant of a TUE are not in fact met; or (d) may be reversed on review by WADA or on appeal.

(ii) In such event, the Athlete shall not be subject to any Consequences based on his/her Use or Possession or Administration of the Prohibited Substance or Prohibited Method in question in accordance with the TUE prior to the effective date of expiry, cancellation, withdrawal or reversal of the TUE. The review pursuant to Regulation 21.7.2 of any subsequent Adverse Analytical Finding shall include consideration of whether such finding is consistent with Use of the Prohibited Substance or Prohibited Method prior to that date, in which event no anti-doping rule violation shall be asserted.

(f) Reviews and Appeals of TUE Decisions

(i) WADA shall review any decision by ISAF not to recognize a TUE granted by the National Anti-Doping Organization that is referred to WADA by the Athlete or the Athlete’s National Anti-Doping Organization. In addition, WADA shall review any decision by ISAF to grant a TUE that is referred to WADA by the Athlete’s National Anti-Doping Organization. WADA may review any other TUE decisions at any time, whether upon request by those affected or on its own initiative. If the TUE decision being reviewed meets the criteria set out in the International Standard for Therapeutic Use Exemptions, WADA will not interfere with it. If the TUE decision does not meet those criteria, WADA will reverse it.

(ii) Any TUE decision by ISAF (or by a National Anti-Doping Organization where it has agreed to consider the application on behalf of ISAF) that is not reviewed by WADA, or that is reviewed by WADA but is not reversed upon review, may be appealed by the Athlete and/or the Athlete’s
National Anti-Doping Organization exclusively to CAS, in accordance with Regulation 21.13.

(iii) A decision by WADA to reverse a TUE decision may be appealed by the Athlete, the National Anti-Doping Organization and/or ISAF exclusively to CAS, in accordance with Regulation 21.13.

(iv) A failure to take action within a reasonable time on a properly submitted application for grant or recognition of a TUE or for review of a TUE decision shall be considered a denial of the application.

21.5 Testing and Investigations

21.5.1 Purpose of Testing and Investigations

Testing and investigations shall only be undertaken for anti-doping purposes. They shall be conducted in conformity with the provisions of the International Standard for Testing and Investigations and the specific protocols of ISAF supplementing that International Standard. (See Appendix 3)

(a) Testing shall be undertaken to obtain analytical evidence as to the Athlete's compliance (or non-compliance) with the strict Code prohibition on the presence/Use of a Prohibited Substance or Prohibited Method. Test distribution planning, Testing, post-Testing activity and all related activities conducted by ISAF shall be in conformity with the International Standard for Testing and Investigations. ISAF shall determine the number of finishing placement tests, random tests and target tests to be performed, in accordance with the criteria established by the International Standard for Testing and Investigations. All provisions of the International Standard for Testing and Investigations shall apply automatically in respect of all such Testing.

(b) Investigations shall be undertaken:

(i) in relation to Atypical Findings, Atypical Passport Findings and Adverse Passport Findings, in accordance with Regulations 21.7.4 and 21.7.5 respectively, gathering intelligence or evidence (including, in particular, analytical evidence) in order to determine whether an anti-doping rule violation has occurred under Regulation 21.2.1 and/or Regulation 21.2.2; and

(ii) in relation to other indications of potential anti-doping rule violations, in accordance with Regulations 21.7.6 and 21.7.7, gathering intelligence or evidence (including, in particular, non-analytical evidence) in order to determine whether an anti-doping rule violation has occurred under any of Regulations 21.2.2 to 21.2.10.

(c) ISAF may obtain, assess and process anti-doping intelligence from all available sources, to inform the development of an effective, intelligent and proportionate test distribution plan, to plan Target Testing, and/or to form the basis of an investigation into a possible anti-doping rule violation(s).
21.5.2 Authority to conduct Testing

(a) Subject to the jurisdictional limitations for Event Testing set out in Article 5.3 of the Code, ISAF shall have In-Competition and Out-of-Competition Testing authority over all of the Athletes specified in the Introduction to these Anti-Doping Rules (under the heading "Scope").

(b) ISAF may require any Athlete over whom it has Testing authority (including any Athlete serving a period of Ineligibility) to provide a Sample at any time and at any place.

(c) WADA shall have In-Competition and Out-of-Competition Testing authority as set out in Article 20.7.8 of the Code.

(d) If ISAF delegates or contracts any part of Testing to a National Anti-Doping Organization (directly or through a MNA), that National Anti-Doping Organization may collect additional Samples or direct the laboratory to perform additional types of analysis at the National Anti-Doping Organization’s expense. If additional Samples are collected or additional types of analysis are performed, ISAF shall be notified.

21.5.3 Event Testing

(a) Except as provided in Article 5.3 of the Code, only a single organization should be responsible for initiating and directing Testing at Event Venues during an Event Period. At International Events, the collection of Samples shall be initiated and directed by ISAF (or any other international organization which is the ruling body for the Event). At the request of ISAF (or any other international organization which is the ruling body for an Event), any Testing during the Event Period outside of the Event Venues shall be coordinated with ISAF (or the relevant ruling body of the Event).

(b) If an Anti-Doping Organization which would otherwise have Testing authority but is not responsible for initiating and directing Testing at an Event desires to conduct Testing of Athletes at the Event Venues during the Event Period, the Anti-Doping Organization shall first confer with ISAF (or any other international organization which is the ruling body of the Event) to obtain permission to conduct and coordinate such Testing. If the Anti-Doping Organization is not satisfied with the response from ISAF (or any other international organization which is the ruling body of the Event), the Anti-Doping Organization may ask WADA for permission to conduct Testing and to determine how to coordinate such Testing, in accordance with the procedures set out in the International Standard for Testing and Investigations. WADA shall not grant approval for such Testing before consulting with and informing ISAF (or any other international organization which is the ruling body for the Event). WADA’s decision shall be final and not subject to appeal. Unless otherwise provided in the authorization to conduct Testing, such tests shall be considered Out-of-Competition tests. Results management for any such test shall be the responsibility of the Anti-Doping Organization initiating the test unless provided otherwise in the rules of the ruling body of the Event.
21.5.4 Test Distribution Planning

Consistent with the International Standard for Testing and Investigations, and in coordination with other Anti-Doping Organizations conducting Testing on the same Athletes, ISAF shall develop and implement an effective, intelligent and proportionate test distribution plan that prioritizes appropriately between disciplines, categories of Athletes, types of Testing, types of Samples collected, and types of Sample analysis, all in compliance with the requirements of the International Standard for Testing and Investigations. ISAF shall provide WADA upon request with a copy of its current test distribution plan.

21.5.5 Coordination of Testing

Where reasonably feasible, Testing shall be coordinated through ADAMS or another system approved by WADA in order to maximize the effectiveness of the combined Testing effort and to avoid unnecessary repetitive Testing.

21.5.6 Athlete Whereabouts Information

(a) ISAF shall identify a Registered Testing Pool of those Athletes who are required to comply with the whereabouts requirements of Annex I to the International Standard for Testing and Investigations, and shall make available through ADAMS, a list which identifies those Athletes included in its Registered Testing Pool either by name or by clearly defined, specific criteria. ISAF shall coordinate with National Anti-Doping Organizations the identification of such Athletes and the collection of their whereabouts information. ISAF shall review and update as necessary its criteria for including Athletes in its Registered Testing Pool, and shall revise the membership of its Registered Testing Pool from time to time as appropriate in accordance with the set criteria. Athletes shall be notified before they are included in a Registered Testing Pool and when they are removed from that pool. Each Athlete in the Registered Testing Pool shall do the following, in each case in accordance with Annex I to the International Standard for Testing and Investigations: (a) advise ISAF of his/her whereabouts on a quarterly basis; (b) update that information as necessary so that it remains accurate and complete at all times; and (c) make him/herself available for Testing at such whereabouts.

(b) For purposes of Regulation 21.2.4, an Athlete’s failure to comply with the requirements of the International Standard for Testing and Investigations shall be deemed a filing failure or a missed test (as defined in the International Standard for Testing and Investigations) where the conditions set forth in the International Standard for Testing and Investigations for declaring a filing failure or missed test are met.

(c) An Athlete in ISAF’s Registered Testing Pool shall continue to be subject to the obligation to comply with the whereabouts requirements of Annex I to the International Standard for Testing and Investigations unless and until (a) the Athlete gives written notice to ISAF that he/she has retired or (b) ISAF has informed him or her that he/she no longer satisfies the criteria for inclusion in ISAF’s Registered Testing Pool.
(d) Whereabouts information relating to an Athlete shall be shared (through ADAMS) with WADA and other Anti-Doping Organizations having authority to test that Athlete, shall be maintained in strict confidence at all times, shall be used exclusively for the purposes set out in Article 5.6 of the Code, and shall be destroyed in accordance with the International Standard for the Protection of Privacy and Personal Information once it is no longer relevant for these purposes.

21.5.7 Retired Athletes Returning to Competition

(a) An Athlete in ISAF’s Registered Testing Pool who has given notice of retirement to ISAF may not resume competing in International Events or National Events until he/she has given ISAF written notice of his/her intent to resume competing and has made him/herself available for Testing for a period of six months before returning to Competition, including (if requested) complying with the whereabouts requirements of Annex I to the International Standard for Testing and Investigations. WADA, in consultation with ISAF and the Athlete’s National Anti-Doping Organization, may grant an exemption to the six-month written notice rule where the strict application of that rule would be manifestly unfair to an Athlete. This decision may be appealed under Regulation 21.13. Any competitive results obtained in violation of this Regulation 21.5.7(a) shall be Disqualified.

(b) If an Athlete retires from sport while subject to a period of Ineligibility, the Athlete shall not resume competing in International Events or National Events until the Athlete has given six months prior written notice (or notice equivalent to the period of Ineligibility remaining as of the date the Athlete retired, if that period was longer than six months) to ISAF and to his/her National Anti-Doping Organization of his/her intent to resume competing and has made him/herself available for Testing for that notice period, including (if requested) complying with the whereabouts requirements of Annex I to the International Standard for Testing and Investigations.

21.5.8 Independent Observer Program

ISAF and the organizing committees for ISAF’s Events, as well as the MNAs and the organizing committees for National Events, shall authorize and facilitate the Independent Observer Program at such Events.

21.6 Analysis of Samples

Samples shall be analyzed in accordance with the following principles:

21.6.1 Use of Accredited and Approved Laboratories
For purposes of Regulation 21.2.1, Samples shall be analyzed only in laboratories accredited or otherwise approved by WADA. The choice of the WADA-accredited or WADA-approved laboratory used for the Sample analysis shall be determined exclusively by ISAF.

21.6.2 Purpose of Analysis of Samples

(a) Samples shall be analyzed to detect Prohibited Substances and Prohibited Methods and other substances as may be directed by WADA pursuant to the Monitoring Program described in Article 4.5 of the Code; or to assist ISAF in profiling relevant parameters in an Athlete’s urine, blood or other matrix, including DNA or genomic profiling; or for any other legitimate anti-doping purpose. Samples may be collected and stored for future analysis.

(b) ISAF shall ask laboratories to analyze Samples in conformity with Article 6.4 of the Code and Article 4.7 of the International Standard for Testing and Investigations.

21.6.3 Research on Samples

No Sample may be used for research without the Athlete’s written consent. Samples used for purposes other than Regulation 21.6.2 shall have any means of identification removed such that they cannot be traced back to a particular Athlete.

21.6.4 Standards for Sample Analysis and Reporting

Laboratories shall analyze Samples and report results in conformity with the International Standard for Laboratories. To ensure effective Testing, the Technical Document referenced at Article 5.4.1 of the Code will establish risk assessment-based Sample analysis menus appropriate for particular sports and sport disciplines, and laboratories shall analyze Samples in conformity with those menus, except as follows:

(a) ISAF may request that laboratories analyze its Samples using more extensive menus than those described in the Technical Document.

(b) ISAF may request that laboratories analyze its Samples using less extensive menus than those described in the Technical Document only if it has satisfied WADA that, because of the particular circumstances of its sport, as set out in its test distribution plan, less extensive analysis would be appropriate.

(c) As provided in the International Standard for Laboratories, laboratories at their own initiative and expense may analyze Samples for Prohibited Substances or Prohibited Methods not included on the Sample analysis menu described in the Technical Document or specified by the Testing authority. Results from any such analysis shall be reported and have the same validity and consequence as any other analytical result.

21.6.5 Further Analysis of Samples
Any Sample may be stored and subsequently subjected to further analysis for the purposes set out in Regulation 21.6.2: (a) by WADA at any time; and/or (b) by ISAF at any time before both the A and B Sample analytical results (or A Sample result where B Sample analysis has been waived or will not be performed) have been communicated by ISAF to the Athlete as the asserted basis for an Regulation 21.2.1 anti-doping rule violation. Such further analysis of Samples shall conform with the requirements of the International Standard for Laboratories and the International Standard for Testing and Investigations.

21.7 Results Management

21.7.1 Responsibility for Conducting Results Management

The circumstances in which ISAF shall take responsibility for conducting results management in respect of anti-doping rule violations involving Athletes and other Persons under its jurisdiction shall be determined by reference to and in accordance with Article 7 of the Code.

7.2 Review of Adverse Analytical Findings From Tests Initiated by ISAF

Results management in respect of the results of tests initiated by ISAF (including tests performed by WADA pursuant to agreement with ISAF) shall proceed as follows:

(a) The results from all analyses must be sent to ISAF in encoded form, in a report signed by an authorized representative of the laboratory. All communication must be conducted confidentially and in conformity with ADAMS.

(b) Upon receipt of an Adverse Analytical Finding, ISAF shall conduct a review to determine whether: (a) an applicable TUE has been granted or will be granted as provided in the International Standard for Therapeutic Use Exemptions, or (b) there is any apparent departure from the International Standard for Testing and Investigations or International Standard for Laboratories that caused the Adverse Analytical Finding.

(c) If the review of an Adverse Analytical Finding under Regulation 21.7.2(b) reveals an applicable TUE or departure from the International Standard for Testing and Investigations or the International Standard for Laboratories that caused the Atypical Finding, the entire test shall be considered negative and the Athlete, the Athlete’s National Anti-Doping Organization and WADA shall be so informed.

7.3 Notification After Review Regarding Adverse Analytical Findings

(a) If the review of an Adverse Analytical Finding under Regulation 21.7.2(b) does not reveal an applicable TUE or entitlement to a TUE as provided in the International Standard for Therapeutic Use Exemptions, or departure from the International Standard for Testing and Investigations or the International Standard for Laboratories that caused the Adverse Analytical Finding, ISAF shall promptly notify the Athlete, and simultaneously the Relevant MNA, the Athlete’s National Anti-Doping Organization and WADA, in the manner set out in Regulation 21.14.1, of: (a) the Adverse Analytical Finding; (b) the anti-doping rule violated; (c) the Athlete’s right to promptly request the analysis of the B Sample or, failing such request, that the B Sample analysis may be deemed
waived; (d) the scheduled date, time and place for the B Sample analysis if the Athlete or ISAF chooses to request an analysis of the B Sample; (e) the opportunity for the Athlete and/or the Athlete's representative to attend the B Sample opening and analysis in accordance with the International Standard for Laboratories if such analysis is requested; and (f) the Athlete's right to request copies of the A and B Sample laboratory documentation package which includes information as required by the International Standard for Laboratories. If ISAF decides not to bring forward the Adverse Analytical Finding as an anti-doping rule violation, it shall so notify the Athlete, the Relevant MNA, the Athlete's National Anti-Doping Organization and WADA.

(b) Where requested by the Athlete or ISAF, arrangements shall be made to analyze the B Sample in accordance with the International Standard for Laboratories. An Athlete may accept the A Sample analytical results by waiving the requirement for B Sample analysis. ISAF may nonetheless elect to proceed with the B Sample analysis.

(c) The Athlete and/or his representative shall be allowed to be present at the analysis of the B Sample. Also, a representative of ISAF as well as a representative of the Relevant MNA shall be allowed to be present.

(d) If the B Sample analysis does not confirm the A Sample analysis, then (unless ISAF takes the case forward as an anti-doping rule violation under Regulation 21.2.2) the entire test shall be considered negative and the Athlete, the Athlete's National Anti-Doping Organization and WADA shall be so informed.

(e) If the B Sample analysis confirms the A Sample analysis, the findings shall be reported to the Athlete, the Relevant MNA, the Athlete's National Anti-Doping Organization and to WADA.

21.7.4 Review of Atypical Findings

(a) As provided in the International Standard for Laboratories, in some circumstances laboratories are directed to report the presence of Prohibited Substances, which may also be produced endogenously, as Atypical Findings, i.e., as findings that are subject to further investigation.

(b) Upon receipt of an Atypical Finding, ISAF shall conduct a review to determine whether: (a) an applicable TUE has been granted or will be granted as provided in the International Standard for Therapeutic Use Exemptions, or (b) there is any apparent departure from the International Standard for Testing and Investigations or International Standard for Laboratories that caused the Atypical Finding.

(c) If the review of an Atypical Finding under Regulation 21.7.4(b) reveals an applicable TUE or a departure from the International Standard for Testing and Investigations or the International Standard for Laboratories that caused the Atypical Finding, the entire test shall be considered negative and the Athlete, the Relevant MNA, the Athlete's National Anti-Doping Organization and WADA shall be so informed.
(d) If that review does not reveal an applicable TUE or a departure from the International Standard for Testing and Investigations or the International Standard for Laboratories that caused the Atypical Finding, ISAF shall conduct the required investigation or cause it to be conducted. After the investigation is completed, either the Atypical Finding will be brought forward as an Adverse Analytical Finding, in accordance with Regulation 21.7.3(a), or else the Athlete, the Relevant MNA, the Athlete’s National Anti-Doping Organization and WADA shall be notified that the Atypical Finding will not be brought forward as an Adverse Analytical Finding.

(e) ISAF will not provide notice of an Atypical Finding until it has completed its investigation and has decided whether it will bring the Atypical Finding forward as an Adverse Analytical Finding unless one of the following circumstances exists:

(i) If ISAF determines the B Sample should be analyzed prior to the conclusion of its investigation, it may conduct the B Sample analysis after notifying the Athlete, with such notice to include a description of the Atypical Finding and the information described in Regulation 21.7.3.1(d)-(f).

(ii) If ISAF is asked (a) by a Major Event Organization shortly before one of its International Events, or (b) by a sport organization responsible for meeting an imminent deadline for selecting team members for an International Event, to disclose whether any Athlete identified on a list provided by the Major Event Organization or sport organization has a pending Atypical Finding, ISAF shall so advise the Major Event Organization or sports organization after first providing notice of the Atypical Finding to the Athlete.

21.7.5 Review of Atypical Passport Findings and Adverse Passport Findings

Review of Atypical Passport Findings and Adverse Passport Findings shall take place as provided in the International Standard for Testing and Investigations and International Standard for Laboratories. At such time as ISAF is satisfied that an anti-doping rule violation has occurred, it shall promptly give the Athlete (and simultaneously the Relevant MNA, the Athlete’s National Anti-Doping Organization and WADA) notice of the anti-doping rule violation asserted and the basis of that assertion.

21.7.6 Review of Whereabouts Failures

ISAF shall review potential filing failures and missed tests, as defined in the International Standard for Testing and Investigations, in respect of Athletes who file their whereabouts information with ISAF, in accordance with Annex I to the International Standard for Testing and Investigations. At such time as ISAF is satisfied that an Regulation 21.2.4 anti-doping rule violation has occurred, it shall promptly give the Athlete (and simultaneously the Relevant MNA, the Athlete’s National Anti-Doping Organization and WADA) notice that it is asserting a violation of Regulation 2.4 and the basis of that assertion.

21.7.7 Review of Other Anti-Doping Rule Violations Not Covered by Regulations 7.2–7.6
ISAF shall conduct any follow-up investigation required into a possible anti-doping rule violation not covered by Regulations 21.7.2-21.7.6. At such time as ISAF is satisfied that an anti-doping rule violation has occurred, it shall promptly give the Athlete or other Person (and simultaneously the Relevant MNA, the Athlete’s or other Person’s National Anti-Doping Organization and WADA) notice of the anti-doping rule violation asserted and the basis of that assertion.

21.7.8 Identification of Prior Anti-Doping Rule Violations

Before giving an Athlete or other Person notice of an asserted anti-doping rule violation as provided above, ISAF shall refer to ADAMS and contact WADA and other relevant Anti-Doping Organizations to determine whether any prior anti-doping rule violation exists.

21.7.9 Provisional Suspensions

(a) **Mandatory Provisional Suspension:** If analysis of an A Sample has resulted in an Adverse Analytical Finding for a Prohibited Substance that is not a Specified Substance, or for a Prohibited Method, and a review in accordance with Regulation 21.7.2(b) does not reveal an applicable TUE or departure from the International Standard for Testing and Investigations or the International Standard for Laboratories that caused the Adverse Analytical Finding, a Provisional Suspension shall be imposed by the Relevant MNA, upon or promptly after the notification described in Regulations 21.7.2, 21.7.3 or 21.7.5.

(b) **Optional Provisional Suspension:** In case of an Adverse Analytical Finding for a Specified Substance, or in the case of any other anti-doping rule violations not covered by Regulation 21.7.9(a), the Relevant MNA, may impose a Provisional Suspension on the Athlete or other Person against whom the anti-doping rule violation is asserted at any time after the review and notification described in Regulations 21.7.2–21.7.7 and prior to the final hearing as described in Regulation 8.

(c) Where a Provisional Suspension is imposed pursuant to Regulation 21.7.9(a) or Regulation 21.7.9(b), the Athlete or other Person shall be given either: (a) an opportunity for a Provisional Hearing either before or on a timely basis after imposition of the Provisional Suspension; or (b) an opportunity for an expedited final hearing in accordance with Regulation 21.8 on a timely basis after imposition of the Provisional Suspension. Furthermore, the Athlete or other Person has a right to appeal from the Provisional Suspension in accordance with Regulation 21.13.2 (save as set out in Regulation 21.7.9(c)(i)).

(i) The Provisional Suspension may be lifted if the Athlete demonstrates to the hearing panel that the violation is likely to have involved a Contaminated Product. A hearing panel’s decision not to lift a mandatory Provisional Suspension on account of the Athlete’s assertion regarding a Contaminated Product shall not be appealable.

(ii) The Provisional Suspension shall be imposed (or shall not be lifted) unless the Athlete or other Person establishes that: (a) the assertion of an anti-doping rule violation has no reasonable prospect of being upheld, e.g., because of a patent flaw in the case against the Athlete or other
Person; or (b) the Athlete or other Person has a strong arguable case that he/she bears No Fault or Negligence for the anti-doping rule violation(s) asserted, so that any period of Ineligibility that might otherwise be imposed for such a violation is likely to be completely eliminated by application of Regulation 21.10.4; or (c) some other facts exist that make it clearly unfair, in all of the circumstances, to impose a Provisional Suspension prior to a final hearing in accordance with Regulation 21.8. This ground is to be construed narrowly, and applied only in truly exceptional circumstances. For example, the fact that the Provisional Suspension would prevent the Athlete or other Person participating in a particular Competition or Event shall not qualify as exceptional circumstances for these purposes.

(d) If a Provisional Suspension is imposed based on an A Sample Adverse Analytical Finding and subsequent analysis of the B Sample does not confirm the A Sample analysis, then the Athlete shall not be subject to any further Provisional Suspension on account of a violation of Regulation 21.2.1. In circumstances where the Athlete (or the Athlete's team) has been removed from a Competition based on a violation of Regulation 21.2.1 and the subsequent B Sample analysis does not confirm the A Sample finding, then if it is still possible for the Athlete or team to be reinserted, without otherwise affecting the Competition, the Athlete or team may continue to take part in the Competition. In addition, the Athlete or team may thereafter take part in other Competitions in the same Event.

(e) In all cases where an Athlete or other Person has been notified of an anti-doping rule violation but a Provisional Suspension has not been imposed on him or her, the Athlete or other Person shall be offered the opportunity to accept a Provisional Suspension voluntarily pending the resolution of the matter.

21.7.10 Resolution Without a Hearing

(a) An Athlete or other Person against whom an anti-doping rule violation is asserted may admit that violation at any time, waive a hearing, and accept the Consequences that are mandated by these Anti-Doping Rules or (where some discretion as to Consequences exists under these Anti-Doping Rules) that have been offered by the Relevant MNA.

(b) Alternatively, if the Athlete or other Person against whom an anti-doping rule violation is asserted fails to dispute that assertion within the deadline specified in the notice sent by the ISAF asserting the violation, then he/she shall be deemed to have admitted the violation, to have waived a hearing, and to have accepted the Consequences that are mandated by these Anti-Doping Rules or (where some discretion as to Consequences exists under these Anti-Doping Rules) that have been offered by the Relevant MNA.

(c) In cases where Regulation 21.7.10(a) or Regulation 21.7.10(b) applies, a hearing before a hearing panel shall not be required. Instead the Relevant MNA, shall promptly issue a written decision confirming the commission of the anti-doping rule violation and the Consequences imposed as a result, and setting out the full reasons for any period of Ineligibility imposed, including (if applicable) a
justification for why the maximum potential period of *Ineligibility* was not imposed. The *Relevant MNA*, shall send copies of that decision to ISAF and other *Anti-Doping Organizations* with a right to appeal under Regulation 21.13.2(c), and shall *Publicly Disclose* that decision in accordance with Regulation 21.14.3(b).

### 21.7.11 Notification of Results Management Decisions

In all cases where ISAF has asserted the commission of an anti-doping rule violation, withdrawn the assertion of an anti-doping rule violation, a *Relevant MNA* has imposed a *Provisional Suspension*, or a *Relevant MNA* has agreed with an *Athlete* or other *Person* on the imposition of *Consequences* without a hearing, ISAF or the *Relevant MNA* (as appropriate) shall give notice thereof in accordance with Regulation 21.14.2(a) to ISAF, the *Relevant MNA*, and other *Anti-Doping Organizations* with a right to appeal under Regulation 21.13.2(c).

### 21.7.12 Retirement from Sport

If an *Athlete* or other *Person* retires while ISAF is conducting the results management process, ISAF retains jurisdiction to complete its results management process. If an *Athlete* or other *Person* retires before any results management process has begun, and ISAF would have had results management authority over the *Athlete* or other *Person* at the time the *Athlete* or other *Person* committed an anti-doping rule violation, ISAF has authority to conduct results management in respect of that anti-doping rule violation.

### 21.8 Right to a Fair Hearing

#### 21.8.1 Principles for a Fair Hearing

(a) When ISAF sends a notice to an *Athlete* or other *Person* asserting an anti-doping rule violation, and the *Athlete* or other *Person* does not waive a hearing in accordance with Regulation 21.7.10(a) or Regulation 21.7.10(b), then the case shall be referred to a hearing panel of the *Relevant MNA* (*the Panel*), for hearing and adjudication.

(b) Hearings shall be scheduled and completed within a reasonable time. Hearings held in connection with *Events* that are subject to these Anti-Doping Rules may be conducted by an expedited process where permitted by the hearing panel.

(c) The *Panel* shall determine the procedure to be followed at the hearing (which may include reference to any rules of procedure adopted by the *Relevant MNA*).

(d) *WADA* and ISAF may attend the hearing as observers. In any event, the *Relevant MNA*, shall keep *WADA* and ISAF fully apprised as to the status of pending cases and the result of all hearings.

(e) The *Panel* shall act in a fair and impartial manner towards all parties at all times.

#### 21.8.2 Decisions

(a) At the end of the hearing, or on a timely basis thereafter, the *Panel* shall issue a written decision that includes the full reasons for the decision and for any period
of Ineligibility imposed, including (if applicable) a justification for why the greatest potential Consequences were not imposed.

(b) The decision may be appealed to the CAS as provided in Regulation 21.13. Copies of the decision shall be provided to the Athlete or other Person, ISAF and to other Anti-Doping Organizations with a right to appeal under Regulation 21.13.2(c).

(c) If no appeal is brought against the decision, then (a) if the decision is that an anti-doping rule violation was committed, the decision shall be Publicly Disclosed as provided in Regulation 21.14.3(b); but (b) if the decision is that no anti-doping rule violation was committed, then the decision shall only be Publicly Disclosed with the consent of the Athlete or other Person who is the subject of the decision. The Relevant MNA shall use reasonable efforts to obtain such consent, and if consent is obtained, shall Publicly Disclose the decision in its entirety or in such redacted form as the Athlete or other Person may approve. The principles contained at Regulation 21.14.3(f) shall be applied in cases involving a Minor.

21.8.3 Single Hearing Before CAS

(a) Cases asserting anti-doping rule violations may be heard directly at CAS, with no requirement for a prior hearing, with the consent of the Athlete, ISAF, the Relevant MNA, WADA, and any other Anti-Doping Organization that would have had a right to appeal a first instance hearing decision to CAS.

(b) If ISAF is satisfied that a Relevant MNA is not conducting the hearing process in accordance with this Code, it may direct that the case be heard directly at CAS. ISAF shall consult with the Athlete, WADA and the Relevant MNA before exercising its discretion under this Regulation.

21.9 Automatic Disqualification of Individual Results

An anti-doping rule violation in Individual Sports in connection with an In-Competition test automatically leads to Disqualification of the result obtained in that Competition with all resulting Consequences, including forfeiture of any medals, points and prizes.

21.10 Sanctions on Individuals

21.10.1 Disqualification of Results in the Event during which an Anti-Doping Rule Violation Occurs

An anti-doping rule violation occurring during or in connection with an Event may, upon the decision of the ruling body of the Event, lead to Disqualification of all of the Athlete’s individual results obtained in that Event with all Consequences, including forfeiture of all medals, points and prizes, except as provided in Regulation 21.10.1(a).

Factors to be included in considering whether to Disqualify other results in an Event might include, for example, the seriousness of the Athlete’s anti-doping rule violation and whether the Athlete tested negative in the other Competitions.
(a) If the Athlete establishes that he or she bears No Fault or Negligence for the violation, the Athlete’s individual results in the other Competitions shall not be Disqualified, unless the Athlete’s results in Competitions other than the Competition in which the anti-doping rule violation occurred were likely to have been affected by the Athlete’s anti-doping rule violation.

21.10.2 Ineligibility for Presence, Use or Attempted Use, or Possession of a Prohibited Substance or Prohibited Method

The period of Ineligibility for a violation of Regulations 21.2.1, 21.2.2 or 21.2.6 shall be as follows, subject to potential reduction or suspension pursuant to Regulations 21.10.4, 21.10.5 or 21.10.6:

(a) The period of Ineligibility shall be four years where:

(i) The anti-doping rule violation does not involve a Specified Substance, unless the Athlete or other Person can establish that the anti-doping rule violation was not intentional.

(ii) The anti-doping rule violation involves a Specified Substance and ISAF can establish that the anti-doping rule violation was intentional.

(b) If Regulation 21.10.2(a) does not apply, the period of Ineligibility shall be two years.

(c) As used in Regulations 21.10.2 and 21.10.3, the term “intentional” is meant to identify those Athletes who cheat. The term therefore requires that the Athlete or other Person engaged in conduct which he or she knew constituted an anti-doping rule violation or knew that there was a significant risk that the conduct might constitute or result in an anti-doping rule violation and manifestly disregarded that risk. An anti-doping rule violation resulting from an Adverse Analytical Finding for a substance which is only prohibited In-Competition shall be rebuttably presumed to be not intentional if the substance is a Specified Substance and the Athlete can establish that the Prohibited Substance was Used Out-of-Competition. An anti-doping rule violation resulting from an Adverse Analytical Finding for a substance which is only prohibited In-Competition shall not be considered intentional if the substance is not a Specified Substance and the Athlete can establish that the Prohibited Substance was Used Out-of-Competition in a context unrelated to sport performance.

21.10.3 Ineligibility for Other Anti-Doping Rule Violations

The period of Ineligibility for anti-doping rule violations other than as provided in Regulation 21.10.2 shall be as follows, unless Regulations 21.10.5 or 21.10.6 are applicable:

(a) For violations of Regulation 21.2.3 or Regulation 21.2.5, the period of Ineligibility shall be four years unless, in the case of failing to submit to Sample collection, the Athlete can establish that the commission of the anti-doping rule violation was not intentional (as defined in Regulation 21.10.2(c)), in which case the period of Ineligibility shall be two years.
(b) For violations of Regulation 21.2.4, the period of Ineligibility shall be two years, subject to reduction down to a minimum of one year, depending on the Athlete's degree of Fault. The flexibility between two years and one year of Ineligibility in this Regulation is not available to Athletes where a pattern of last-minute whereabouts changes or other conduct raises a serious suspicion that the Athlete was trying to avoid being available for Testing.

(c) For violations of Regulation 21.2.7 or 21.2.8, the period of Ineligibility shall be a minimum of four years up to lifetime Ineligibility, depending on the seriousness of the violation. An Regulation 21.2.7 or Regulation 21.2.8 violation involving a Minor shall be considered a particularly serious violation and, if committed by Athlete Support Personnel for violations other than for Specified Substances, shall result in lifetime Ineligibility for Athlete Support Personnel. In addition, significant violations of Regulation 21.2.7 or 21.2.8 which may also violate non-sporting laws and regulations, shall be reported to the competent administrative, professional or judicial authorities.

(d) For violations of Regulation 21.2.9, the period of Ineligibility imposed shall be a minimum of two years, up to four years, depending on the seriousness of the violation.

(e) For violations of Regulation 21.2.10, the period of Ineligibility shall be two years, subject to reduction down to a minimum of one year, depending on the Athlete or other Person's degree of Fault and other circumstances of the case.

21.10.4 Elimination of the Period of Ineligibility where there is No Fault or Negligence

If an Athlete or other Person establishes in an individual case that he or she bears No Fault or Negligence, then the otherwise applicable period of Ineligibility shall be eliminated.

21.10.5 Reduction of the Period of Ineligibility based on No Significant Fault or Negligence

(a) Reduction of Sanctions for Specified Substances or Contaminated Products for Violations of Regulation 21.2.1, 21.2.2 or 21.2.6.

(i) Specified Substances

Where the anti-doping rule violation involves a Specified Substance, and the Athlete or other Person can establish No Significant Fault or Negligence, then the period of Ineligibility shall be, at a minimum, a reprimand and no period of Ineligibility, and at a maximum, two years of Ineligibility, depending on the Athlete's or other Person's degree of Fault.

(ii) Contaminated Products

In cases where the Athlete or other Person can establish No Significant Fault or Negligence and that the detected Prohibited Substance came from a Contaminated Product, then the period of Ineligibility shall be, at a minimum, a reprimand and no period of Ineligibility, and at a maximum, two years Ineligibility, depending on the Athlete's or other Person's degree of Fault.
(b) Application of No Significant Fault or Negligence beyond the Application of Regulation 21.10.5(a)

If an Athlete or other Person establishes in an individual case where Regulation 21.10.5(a) is not applicable that he or she bears No Significant Fault or Negligence, then, subject to further reduction or elimination as provided in Regulation 21.10.6, the otherwise applicable period of Ineligibility may be reduced based on the Athlete or other Person’s degree of Fault, but the reduced period of Ineligibility may not be less than one-half of the period of Ineligibility otherwise applicable. If the otherwise applicable period of Ineligibility is a lifetime, the reduced period under this Regulation may be no less than eight years.

21.10.6 Elimination, Reduction, or Suspension of Period of Ineligibility or other Consequences for Reasons Other than Fault

(a) Substantial Assistance in Discovering or Establishing Anti-Doping Rule Violations

(i) ISAF may, prior to a final appellate decision under Regulation 21.13 or the expiration of the time to appeal, suspend a part of the period of Ineligibility imposed in an individual case in which it has results management authority where the Athlete or other Person has provided Substantial Assistance to an Anti-Doping Organization, criminal authority or professional disciplinary body which results in: (i) the Anti-Doping Organization discovering or bringing forward an anti-doping rule violation by another Person, or (ii) which results in a criminal or disciplinary body discovering or bringing forward a criminal offense or the breach of professional rules committed by another Person and the information provided by the Person providing Substantial Assistance is made available to ISAF. After a final appellate decision under Regulation 21.13 or the expiration of time to appeal, ISAF may only suspend a part of the otherwise applicable period of Ineligibility with the approval of WADA. The extent to which the otherwise applicable period of Ineligibility may be suspended shall be based on the seriousness of the anti-doping rule violation committed by the Athlete or other Person and the significance of the Substantial Assistance provided by the Athlete or other Person to the effort to eliminate doping in sport. No more than three-quarters of the otherwise applicable period of Ineligibility may be suspended. If the otherwise applicable period of Ineligibility is a lifetime, the non-suspended period under this Regulation must be no less than eight years. If the Athlete or other Person fails to continue to cooperate and to provide the complete and credible Substantial Assistance upon which a suspension of the period of Ineligibility was based, ISAF shall reinstate the original period of Ineligibility. If ISAF decides to reinstate a suspended period of Ineligibility or decides not to reinstate a suspended period of Ineligibility, that decision may be appealed by any Person entitled to appeal under Regulation 21.13.

(ii) To further encourage Athletes and other Persons to provide Substantial Assistance to Anti-Doping Organizations, at the request of ISAF or at the request of the Athlete or other Person who has (or has been asserted to
have) committed an anti-doping rule violation, WADA may agree at any stage of the results management process, including after a final appellate decision under Regulation 21.13, to what it considers to be an appropriate suspension of the otherwise-applicable period of Ineligibility and other Consequences. In exceptional circumstances, WADA may agree to suspensions of the period of Ineligibility and other Consequences for Substantial Assistance greater than those otherwise provided in this Regulation, or even no period of Ineligibility, and/or no return of prize money or payment of fines or costs. WADA’s approval shall be subject to reinstatement of sanction, as otherwise provided in this Regulation. Notwithstanding Regulation 21.13, WADA’s decisions in the context of this Regulation may not be appealed by any other Anti-Doping Organization.

(iii) If ISAF suspends any part of an otherwise applicable sanction because of Substantial Assistance, then notice providing justification for the decision shall be provided to the other Anti-Doping Organizations with a right to appeal under Regulation 21.13.2(c) as provided in Regulation 21.14.2. In unique circumstances where WADA determines that it would be in the best interest of anti-doping, WADA may authorize ISAF to enter into appropriate confidentiality agreements limiting or delaying the disclosure of the Substantial Assistance agreement or the nature of Substantial Assistance being provided.

(b) Admission of an Anti-Doping Rule Violation in the Absence of Other Evidence

Where an Athlete or other Person voluntarily admits the commission of an anti-doping rule violation before having received notice of a Sample collection which could establish an anti-doping rule violation (or, in the case of an anti-doping rule violation other than Regulation 21.2.1, before receiving first notice of the admitted violation pursuant to Regulation 21.7) and that admission is the only reliable evidence of the violation at the time of admission, then the period of Ineligibility may be reduced, but not below one-half of the period of Ineligibility otherwise applicable.

(c) Prompt Admission of an Anti-Doping Rule Violation after being Confronted with a Violation Sanctionable under Regulation 21.10.2(a) or Regulation 21.10.3(a)

An Athlete or other Person potentially subject to a four-year sanction under Regulation 21.10.2(a) or 21.10.3(a) (for evading or refusing Sample Collection or Tampering with Sample Collection), by promptly admitting the asserted anti-doping rule violation after being confronted by ISAF, and also upon the approval and at the discretion of both WADA and ISAF, may receive a reduction in the period of Ineligibility down to a minimum of two years, depending on the seriousness of the violation and the Athlete or other Person’s degree of Fault.

(d) Application of Multiple Grounds for Reduction of a Sanction

Where an Athlete or other Person establishes entitlement to reduction in sanction under more than one provision of Regulation 21.10.4, 21.10.5 or 21.10.6, before applying any reduction or suspension under Regulation 21.10.6, the otherwise applicable period of
Ineligibility shall be determined in accordance with Regulations 21.10.2, 21.10.3, 21.10.4, and 21.10.5. If the Athlete or other Person establishes entitlement to a reduction or suspension of the period of Ineligibility under Regulation 21.10.6, then the period of Ineligibility may be reduced or suspended, but not below one-fourth of the otherwise applicable period of Ineligibility.

21.10.7 Multiple Violations

(a) For an Athlete or other Person's second anti-doping rule violation, the period of Ineligibility shall be the greater of:

(i) six months;

(ii) one-half of the period of Ineligibility imposed for the first anti-doping rule violation without taking into account any reduction under Regulation 10.6; or

(iii) twice the period of Ineligibility otherwise applicable to the second anti-doping rule violation treated as if it were a first violation, without taking into account any reduction under Regulation 21.10.6.

The period of Ineligibility established above may then be further reduced by the application of Regulation 21.10.6.

(b) A third anti-doping rule violation will always result in a lifetime period of Ineligibility, except if the third violation fulfills the condition for elimination or reduction of the period of Ineligibility under Regulation 21.10.4 or 21.10.5, or involves a violation of Regulation 21.2.4. In these particular cases, the period of Ineligibility shall be from eight years to lifetime Ineligibility.

(c) An anti-doping rule violation for which an Athlete or other Person has established No Fault or Negligence shall not be considered a prior violation for purposes of this Regulation.

(d) Additional Rules for Certain Potential Multiple Violations

(i) For purposes of imposing sanctions under Regulation 21.10.7, an anti-doping rule violation will only be considered a second violation if ISAF can establish that the Athlete or other Person committed the second anti-doping rule violation after the Athlete or other Person received notice pursuant to Regulation 21.7, or after ISAF made reasonable efforts to give notice of the first anti-doping rule violation. If ISAF cannot establish this, the violations shall be considered together as one single first violation, and the sanction imposed shall be based on the violation that carries the more severe sanction.

(ii) If, after the imposition of a sanction for a first anti-doping rule violation, ISAF discovers facts involving an anti-doping rule violation by the Athlete or other Person which occurred prior to notification regarding the first
violation, then ISAF shall impose an additional sanction based on the sanction that could have been imposed if the two violations had been adjudicated at the same time. Results in all Competitions dating back to the earlier anti-doping rule violation will be Disqualified as provided in Regulation 21.10.8.

(e) Multiple Anti-Doping Rule Violations during Ten-Year Period

For purposes of Regulation 21.10.7, each anti-doping rule violation must take place within the same ten-year period in order to be considered multiple violations.

21.10.8 Disqualification of Results in Competitions Subsequent to Sample Collection or Commission of an Anti-Doping Rule Violation

In addition to the automatic Disqualification of the results in the Competition which produced the positive Sample under Regulation 21.9, all other competitive results of the Athlete obtained from the date a positive Sample was collected (whether In-Competition or Out-of-Competition), or other anti-doping rule violation occurred, through the commencement of any Provisional Suspension or Ineligibility period, shall, unless fairness requires otherwise, be Disqualified with all of the resulting Consequences including forfeiture of any medals, points and prizes.

21.10.9 Allocation of CAS Cost Awards and Forfeited Prize Money

The priority for repayment of CAS cost awards and forfeited prize money shall be: first, payment of costs awarded by CAS; and second, reimbursement of the expenses of the Relevant MNA and ISAF (in the proportions they were incurred).

21.10.10 Financial Consequences

Intentionally left blank.

21.10.11 Commencement of Ineligibility Period

Except as provided below, the period of Ineligibility shall start on the date of the final hearing decision providing for Ineligibility or, if the hearing is waived or there is no hearing, on the date Ineligibility is accepted or otherwise imposed.

(a) Delays Not Attributable to the Athlete or other Person

Where there have been substantial delays in the hearing process or other aspects of Doping Control not attributable to the Athlete or other Person, ISAF may start the period of Ineligibility at an earlier date commencing as early as the date of Sample collection or the date on which another anti-doping rule violation last occurred. All competitive results achieved during the period of Ineligibility, including retroactive Ineligibility, shall be Disqualified.

(b) Timely Admission

Where the Athlete or other Person promptly (which, in all events, for an Athlete means before the Athlete competes again) admits the anti-doping rule violation after being confronted with the anti-doping rule violation by ISAF, the period of Ineligibility may
start as early as the date of Sample collection or the date on which another anti-doping rule violation last occurred. In each case, however, where this Regulation is applied, the Athlete or other Person shall serve at least one-half of the period of Ineligibility going forward from the date the Athlete or other Person accepted the imposition of a sanction, the date of a hearing decision imposing a sanction, or the date the sanction is otherwise imposed. This Regulation shall not apply where the period of Ineligibility has already been reduced under Regulation 21.10.6(c).

(c) Credit for Provisional Suspension or Period of Ineligibility Served

(i) If a Provisional Suspension is imposed and respected by the Athlete or other Person, then the Athlete or other Person shall receive a credit for such period of Provisional Suspension against any period of Ineligibility which may ultimately be imposed. If a period of Ineligibility is served pursuant to a decision that is subsequently appealed, then the Athlete or other Person shall receive a credit for such period of Ineligibility served against any period of Ineligibility which may ultimately be imposed on appeal.

(ii) If an Athlete or other Person voluntarily accepts a Provisional Suspension in writing from ISAF and thereafter respects the Provisional Suspension, the Athlete or other Person shall receive a credit for such period of voluntary Provisional Suspension against any period of Ineligibility which may ultimately be imposed. A copy of the Athlete or other Person’s voluntary acceptance of a Provisional Suspension shall be provided promptly to each party entitled to receive notice of an asserted anti-doping rule violation under Regulation 21.14.1.

(iii) No credit against a period of Ineligibility shall be given for any time period before the effective date of the Provisional Suspension or voluntary Provisional Suspension regardless of whether the Athlete elected not to compete or was suspended by his or her team.

(iv) In Team Sports, where a period of Ineligibility is imposed upon a team, unless fairness requires otherwise, the period of Ineligibility shall start on the date of the final hearing decision providing for Ineligibility or, if the hearing is waived, on the date Ineligibility is accepted or otherwise imposed. Any period of team Provisional Suspension (whether imposed or voluntarily accepted) shall be credited against the total period of Ineligibility to be served.

21.10.12 Status During Ineligibility

(a) Prohibition Against Participation During Ineligibility

No Athlete or other Person who has been declared Ineligible may, during the period of Ineligibility, participate in any capacity in a Competition or activity (other than authorized anti-doping education or rehabilitation programs) authorized or organized by ISAF or any MNA or a club or other member organization of ISAF or any MNA, or in Competitions authorized or organized by any professional league or any international or
An Athlete or other Person subject to a period of Ineligibility longer than four years may, after completing four years of the period of Ineligibility, participate as an Athlete in local sport events not sanctioned or otherwise under the jurisdiction of a Code Signatory or member of a Code Signatory, but only so long as the local sport event is not at a level that could otherwise qualify such Athlete or other Person directly or indirectly to compete in (or accumulate points toward) a national championship or International Event, and does not involve the Athlete or other Person working in any capacity with Minors.

An Athlete or other Person subject to a period of Ineligibility shall remain subject to Testing.

(b) Return to Training

As an exception to Regulation 21.10.12(a), an Athlete may return to train with a team or to use the facilities of a club or other member organization of ISAF’s member organization during the shorter of: (1) the last two months of the Athlete’s period of Ineligibility, or (2) the last one-quarter of the period of Ineligibility imposed.

(c) Violation of the Prohibition of Participation During Ineligibility

Where an Athlete or other Person who has been declared Ineligible violates the prohibition against participation during Ineligibility described in Regulation 21.10.12(a), the results of such participation shall be Disqualified and a new period of Ineligibility equal in length up to the original period of Ineligibility shall be added to the end of the original period of Ineligibility. The new period of Ineligibility may be adjusted based on the Athlete or other Person’s degree of Fault and other circumstances of the case. The determination of whether an Athlete or other Person has violated the prohibition against participation, and whether an adjustment is appropriate, shall be made by ISAF. This decision may be appealed under Regulation 21.13.

Where an Athlete Support Person or other Person assists a Person in violating the prohibition against participation during Ineligibility, ISAF shall impose sanctions for a violation of Regulation 21.2.9 for such assistance.

(d) Withholding of Financial Support during Ineligibility

In addition, for any anti-doping rule violation not involving a reduced sanction as described in Regulation 21.10.4 or 21.10.5, some or all sport-related financial support or other sport-related benefits received by such Person will be withheld by ISAF and its MNAs.

21.10.13 Automatic Publication of Sanction

A mandatory part of each sanction shall include automatic publication, as provided in Regulation 21.14.3.
21.11 Consequences to Teams

21.11.1 Testing of Teams Sports (Alternative 1 for Teams of more than 3)

Where one member of a team has been notified of an anti-doping rule violation under Regulation 21.7 in connection with an Event, the ruling body for the Event shall conduct appropriate Target Testing of all members of the team during the Event Period.

21.11.2 Consequences for Team Sports

If more than two members of a team in a Team Sport are found to have committed an anti-doping rule violation during an Event Period, the ruling body of the Event shall impose an appropriate sanction on the team (e.g., loss of points, Disqualification from a Competition or Event, or other sanction) in addition to any Consequences imposed upon the individual Athletes committing the anti-doping rule violation.

21.11.3 Event Ruling Body may Establish Stricter Consequences for Team Sports

The ruling body for an Event may elect to establish rules for the Event which impose Consequences for Team Sports stricter than those in Regulation 21.11.2 for the purposes of the Event.

21.11.4 The boat and its crewmembers may be subject to such further disciplinary action by the Protest Committee, Jury or ISAF Disciplinary Commission as deemed appropriate, when satisfied that there has been a breaching Racing Rule of Sailing 2 (Fair Sailing).

Consequences for Teams (Alternative 2 for Teams of 2)

21.11.5 Testing of Teams

Where one member of a team (outside of Team Sports) has been notified of an anti-doping rule violation under Regulation 21.7 in connection with an Event, the ruling body for the Event shall conduct appropriate Target Testing of all members of the team during the Event Period.

21.11.6 Consequences for Teams

(a) An anti-doping rule violation committed by a member of a team in connection with an In-Competition test automatically leads to Disqualification of the result obtained by the team in that Competition, with all resulting consequences for the team and its members, including forfeiture of any medals, points and prizes.

(b) An anti-doping rule violation committed by a member of a team occurring during or in connection with an Event may lead to Disqualification of all of the results obtained by the team in that Event with all consequences for the team and its members, including forfeiture of all medals, points and prizes, except as provided in Regulation 21.11.2(c).
(c) Where an Athlete who is a member of a team committed an anti-doping rule violation during or in connection with one Competition in an Event, if the other member(s) of the team establish(es) that he/she/they bear(s) No Fault or Negligence for that violation, the results of the team in any other Competition(s) in that Event shall not be Disqualified unless the results of the team in the Competition(s) other than the Competition in which the anti-doping rule violation occurred were likely to have been affected by the Athlete's anti-doping rule violation.

The boat and its crewmembers may be subject to such further disciplinary action by the Protest Committee, Jury or ISAF Disciplinary Commission as deemed appropriate, when satisfied that there has been a breaching Racing Rule of Sailing 2 (Fair Sailing).

21.12 Sanctions and Costs Assessed Against Sporting Bodies

12.1 ISAF has the authority to withhold some or all funding or other non-financial support to MNAs that are not in compliance with these Anti-Doping Rules.

21.13 Appeals

21.13.1 Decisions Subject to Appeal

Decisions made under these Anti-Doping Rules may be appealed as set forth below in Regulation 21.2 through 21.7 or as otherwise provided in these Anti-Doping Rules, the Code or the International Standards. Such decisions shall remain in effect while under appeal unless the appellate body orders otherwise. Before an appeal is commenced, any post-decision review provided in the Anti-Doping Organization's rules must be exhausted, provided that such review respects the principles set forth in Regulation 21.2.2 below (except as provided in Regulation 21.1.3).

(a) Scope of Review Not Limited

The scope of review on appeal includes all issues relevant to the matter and is expressly not limited to the issues or scope of review before the initial decision maker.

(b) CAS Shall Not Defer to the Findings Being Appealed

In making its decision, CAS need not give deference to the discretion exercised by the body whose decision is being appealed.

(c) WADA Not Required to Exhaust Internal Remedies

Where WADA has a right to appeal under Regulation 21.13 and no other party has appealed a final decision within ISAF and its MNA’s process, WADA may appeal such decision directly to CAS without having to exhaust other remedies in ISAF and its MNA’s process.

21.13.2 Appeals from Decisions Regarding Anti-Doping Rule Violations, Consequences,
Provisional Suspensions, Recognition of Decisions and Jurisdiction

A decision that an anti-doping rule violation was committed, a decision imposing Consequences or not imposing Consequences for an anti-doping rule violation, or a decision that no anti-doping rule violation was committed; a decision that an anti-doping rule violation proceeding cannot go forward for procedural reasons (including, for example, prescription); a decision by WADA not to grant an exception to the six months notice requirement for a retired Athlete to return to Competition under Regulation 21.5.7(a); a decision by WADA assigning results management under Article 7.1 of the Code; a decision by ISAF not to bring forward an Adverse Analytical Finding or an Atypical Finding as an anti-doping rule violation, or a decision not to go forward with an anti-doping rule violation after an investigation under Regulation 21.7.7; a decision to impose a Provisional Suspension as a result of a Provisional Hearing; ISAF’s failure to comply with Regulation 21.7.9; a decision that ISAF and/or its MNA lacks jurisdiction to rule on an alleged anti-doping rule violation or its Consequences; a decision to suspend, or not suspend, a period of Ineligibility or to reinstate, or not reinstate, a suspended period of Ineligibility under Regulation 21.10.6(a); a decision under Regulation 21.10.12(c); and a decision by ISAF not to recognize another Anti-Doping Organization’s decision under Regulation 21.15, may be appealed exclusively as provided in Regulations 21.13.2 – 21.13.7.

(a) Appeals Involving International-Level Athletes or International Events

In cases arising from participation in an International Event or in cases involving International-Level Athletes, the decision may be appealed exclusively to CAS.

(b) Appeals Involving Other Athletes or Other Persons

In cases where Regulation 21.13.2(a) is not applicable, the decision may be appealed to a national-level appeal body, being an independent and impartial body established in accordance with rules adopted by the National Anti-Doping Organization having jurisdiction over the Athlete or other Person. The rules for such appeal shall respect the following principles: a timely hearing; a fair and impartial hearing panel; the right to be represented by counsel at the Person's own expense; and a timely, written, reasoned decision. If the National Anti-Doping Organization has not established such a body, the decision may be appealed to CAS in accordance with the provisions applicable before such court.

(c) Persons Entitled to Appeal

In cases under Regulation 21.13.2(a), the following parties shall have the right to appeal to CAS: (a) the Athlete or other Person who is the subject of the decision being appealed; (b) the other party to the case in which the decision was rendered; (c) ISAF; (d) the National Anti-Doping Organization of the Person’s country of residence or countries where the Person is a national or license holder; (e) the International Olympic Committee or International Paralympic Committee, as applicable, where the decision may have an effect in relation to the Olympic Games or Paralympic Games, including decisions affecting eligibility for the Olympic Games or Paralympic Games; and (f) WADA.

In cases under Regulation 21.13.2(b), the parties having the right to appeal to the national-level appeal body shall be as provided in the National Anti-Doping
Submission: 012-14  Cont’d

Organization's rules but, at a minimum, shall include the following parties: (a) the Athlete or other Person who is the subject of the decision being appealed; (b) the other party to the case in which the decision was rendered; (c) ISAF; (d) the National Anti-Doping Organization of the Person's country of residence; (e) the International Olympic Committee or International Paralympic Committee, as applicable, where the decision may have an effect in relation to the Olympic Games or Paralympic Games, including decisions affecting eligibility for the Olympic Games or Paralympic Games; and (f) WADA. For cases under Regulation 21.13(b)(ii), WADA, the International Olympic Committee, the International Paralympic Committee, and ISAF shall also have the right to appeal to CAS with respect to the decision of the national-level appeal body. Any party filing an appeal shall be entitled to assistance from CAS to obtain all relevant information from the Anti-Doping Organization whose decision is being appealed and the information shall be provided if CAS so directs.

Notwithstanding any other provision herein, the only Person who may appeal from a Provisional Suspension is the Athlete or other Person upon whom the Provisional Suspension is imposed.

(d) Cross Appeals and other Subsequent Appeals Allowed

Cross appeals and other subsequent appeals by any respondent named in cases brought to CAS under the Code are specifically permitted. Any party with a right to appeal under this Regulation 13 must file a cross appeal or subsequent appeal at the latest with the party’s answer.

21.13.3 Failure to Render a Timely Decision

Where, in a particular case, ISAF and/or its MNAs fails to render a decision with respect to whether an anti-doping rule violation was committed within a reasonable deadline set by WADA, WADA may elect to appeal directly to CAS as if ISAF and its MNAs had rendered a decision finding no anti-doping rule violation. If the CAS hearing panel determines that an anti-doping rule violation was committed and that WADA acted reasonably in electing to appeal directly to CAS, then WADA’s costs and attorney fees in prosecuting the appeal shall be reimbursed to WADA by ISAF and/or its MNAs.

21.13.4 Appeals Relating to TUEs

TUE decisions may be appealed exclusively as provided in Regulation 21.4.4.

21.13.5 Notification of Appeal Decisions

Any Anti-Doping Organization that is a party to an appeal shall promptly provide the appeal decision to the Athlete or other Person and to the other Anti-Doping Organizations that would have been entitled to appeal under Regulation 21.13.2(c) as provided under Regulation 21.14.2.

21.13.6 Appeal from Decisions Pursuant to Regulation 12

Decisions by ISAF pursuant to Regulation 21.12 may be appealed exclusively to CAS by the MNA.
21.13.7 Time for Filing Appeals

(a) Appeals to CAS

The time to file an appeal to CAS shall be twenty-one days from the date of receipt of the decision by the appealing party. The above notwithstanding, the following shall apply in connection with appeals filed by a party entitled to appeal but which was not a party to the proceedings that led to the decision being appealed:

(i) Within fifteen days from notice of the decision, such party/ies shall have the right to request a copy of the case file from the body that issued the decision;

(ii) If such a request is made within the fifteen-day period, then the party making such request shall have twenty-one days from receipt of the file to file an appeal to CAS.

The above notwithstanding, the filing deadline for an appeal filed by WADA shall be the later of:

(i) Twenty-one days after the last day on which any other party in the case could have appealed; or

(ii) Twenty-one days after WADA’s receipt of the complete file relating to the decision.

(b) Appeals Under Regulation 21.13.2(b)

The time to file an appeal to an independent and impartial body established at national level in accordance with rules established by the National Anti-Doping Organization shall be indicated by the same rules of the National Anti-Doping Organization.

The above notwithstanding, the filing deadline for an appeal or intervention filed by WADA shall be the later of:

(i) Twenty-one days after the last day on which any other party in the case could have appealed, or

(ii) Twenty-one days after WADA’s receipt of the complete file relating to the decision.

21.14 Confidentiality and Reporting

21.14.1 Information Concerning Adverse Analytical Findings, Atypical Findings, and Other Asserted Anti-Doping Rule Violations

(a) Notice of Anti-Doping Rule Violations to Athletes and other Persons Notice to Athletes or other Persons of anti-doping rule violations asserted against
them shall occur as provided under Regulations 21.7 and 21.14 of these Anti-Doping Rules.

(b) Notice of Anti-Doping Rule Violations to National Anti-Doping Organizations and WADA

Notice of the assertion of an anti-doping rule violation to National Anti-Doping Organizations and WADA shall occur as provided under Regulations 21.7 and 21.14 of these Anti-Doping Rules, simultaneously with the notice to the Athlete or other Person.

(c) Content of an Anti-Doping Rule Violation Notice

Notification of an anti-doping rule violation under Regulation 21.2.1 shall include: the Athlete’s name, country, sport and discipline within the sport, the Athlete’s competitive level, whether the test was In-Competition or Out-of-Competition, the date of Sample collection, the analytical result reported by the laboratory, and other information as required by the International Standard for Testing and Investigations.

Notice of anti-doping rule violations other than under Regulation 21.2.1 shall include the rule violated and the basis of the asserted violation.

(d) Status Reports

Except with respect to investigations which have not resulted in notice of an anti-doping rule violation pursuant to Regulation 21.14.1(a), National Anti-Doping Organizations and WADA shall be regularly updated on the status and findings of any review or proceedings conducted pursuant to Regulation 21.7, 21.8 or 21.13 and shall be provided with a prompt written reasoned explanation or decision explaining the resolution of the matter.

(e) Confidentiality

The recipient organizations shall not disclose this information beyond those Persons with a need to know (which would include the appropriate personnel at the applicable National Olympic Committee, MNA, and team in a Team Sport) until ISAF has made Public Disclosure or has failed to make Public Disclosure as required in Regulation 21.14.3.

(f) ISAF shall ensure that information concerning Adverse Analytical Findings, Atypical Findings, and other asserted anti-doping rule violations remains confidential until such information is Publicly Disclosed in accordance with Regulation 21.14.3.
21.14.2 Notice of Anti-Doping Rule Violation Decisions and Request for Files

(a) Anti-doping rule violation decisions rendered pursuant to Regulation 21.7.11, 21.8.2, 21.10.4, 21.10.5, 21.10.6, 21.10.12(c) or 21.13.5 shall include the full reasons for the decision, including, if applicable, a justification for why the greatest possible Consequences were not imposed. Where the decision is not in English or French, the Relevant MNA shall provide a short English or French summary of the decision and the supporting reasons.

(b) An Anti-Doping Organization having a right to appeal a decision received pursuant to Regulation 21.14.2(a) or ISAF may, within fifteen days of receipt, request a copy of the full case file pertaining to the decision.

21.14.3 Public Disclosure

(a) The identity of any Athlete or other Person who is asserted by the Relevant MNA to have committed an anti-doping rule violation may be Publicly Disclosed by the Relevant MNA only after notice has been provided to the Athlete or other Person in accordance with Regulation 21.7.3, 21.7.4, 21.7.5, 21.7.6 or 21.7.7 and simultaneously to WADA, ISAF, and the National Anti-Doping Organization of the Athlete or other Person in accordance with Regulation 21.14.1(b).

(b) No later than twenty days after it has been determined in a final appellate decision under Regulation 21.13.2(a) or 21.13.2(b), or such appeal has been waived, or a hearing in accordance with Regulation 21.8 has been waived, the Relevant MNA the assertion of an anti-doping rule violation has not been timely challenged, ISAF must Publicly Report the disposition of the matter, including the sport, the anti-doping rule violated, the name of the Athlete or other Person committing the violation, the Prohibited Substance or Prohibited Method involved (if any), and the Consequences imposed. The Relevant MNA must also Publicly Report within twenty days the results of final appeal decisions concerning anti-doping rule violations, including the information described above.

(c) In any case where it is determined, after a hearing or appeal, that the Athlete or other Person did not commit an anti-doping rule violation, the decision may be Publicly Disclosed only with the consent of the Athlete or other Person who is the subject of the decision. The Relevant MNA shall use reasonable efforts to obtain such consent. If consent is obtained, the Relevant MNA shall Publicly Disclose the decision in its entirety or in such redacted form as the Athlete or other Person may approve.

(d) Publication shall be accomplished at a minimum by placing the required information on the Relevant MNA website or publishing it through other means and leaving the information up for the longer of one month or the duration of any period of Ineligibility.

(e) Neither ISAF, nor its MNAs, nor any official of either body, shall publicly comment on the specific facts of any pending case (as opposed to general description of process and science) except in response to public comments attributed to the Athlete or other Person against whom an anti-doping rule violation is asserted, or
their representatives.

(f) The mandatory Public Reporting required in Regulation 21.14.3(b) shall not be required where the Athlete or other Person who has been found to have committed an anti-doping rule violation is a Minor. Any optional Public Reporting in a case involving a Minor shall be proportionate to the facts and circumstances of the case.

21.14.4 Statistical Reporting

ISAF shall publish at least annually a general statistical report of its Doping Control activities, with a copy provided to WADA. ISAF may also publish reports showing the name of each Athlete tested and the date of each Testing.

21.14.5 Doping Control Information Clearinghouse

To facilitate coordinated test distribution planning and to avoid unnecessary duplication in Testing by the various Anti-Doping Organizations, ISAF shall report all In-Competition and Out-of-Competition tests on such Athletes to the WADA clearinghouse, using ADAMS, as soon as possible after such tests have been conducted. This information will be made accessible, where appropriate and in accordance with the applicable rules, to the Athlete, the Athlete's National Anti-Doping Organization and any other Anti-Doping Organizations with Testing authority over the Athlete.

21.14.6 Data Privacy

(a) ISAF and MNAs may collect, store, process or disclose personal information relating to Athletes and other Persons where necessary and appropriate to conduct their anti-doping activities under the Code, the International Standards (including specifically the International Standard for the Protection of Privacy and Personal Information) and these Anti-Doping Rules.

(b) Any Participant who submits information including personal data to any Person in accordance with these Anti-Doping Rules shall be deemed to have agreed, pursuant to applicable data protection laws and otherwise, that such information may be collected, processed, disclosed and used by such Person for the purposes of the implementation of these Anti-Doping Rules, in accordance with the International Standard for the Protection of Privacy and Personal Information and otherwise as required to implement these Anti-Doping Rules.

21.15 Application and Recognition of Decisions

21.15.1 Subject to the right to appeal provided in Regulation 21.13, Testing, hearing results or other final adjudications of any Signatory which are consistent with the Code and are within that Signatory's authority shall be applicable worldwide and shall be recognized and respected by ISAF and all its MNAs.
21.15.2 ISAF and its MNAs shall recognize the measures taken by other bodies which have not accepted the Code if the rules of those bodies are otherwise consistent with the Code.

21.15.3 Subject to the right to appeal provided in Regulation 21.13, any decision of ISAF regarding a violation of these Anti-Doping Rules shall be recognized by all MNAs, which shall take all necessary action to render such decision effective.

21.16 Incorporation of ISAF Anti-Doping Rules and Obligations of MNAs

21.16.1 All MNAs and their members shall comply with these Anti-Doping Rules. All MNAs and other members shall include in their regulations the provisions necessary to ensure that ISAF may enforce these Anti-Doping Rules directly as against Athletes under their anti-doping jurisdiction (including National-Level Athletes). These Anti-Doping Rules shall also be incorporated either directly or by reference into each MNA’s rules so that the MNA may enforce them itself directly as against Athletes under its anti-doping jurisdiction (including National-Level Athletes).

21.16.2 All MNAs shall establish rules requiring all Athletes and each Athlete Support Personnel who participates as coach, trainer, manager, team staff, official, medical or paramedical personnel in a Competition or activity authorized or organized by a MNA or one of its member organizations to agree to be bound by these Anti-Doping Rules and to submit to the results management authority of the Anti-Doping Organization responsible under the Code as a condition of such participation.

21.16.3 All MNAs shall report any information suggesting or relating to an anti-doping rule violation to ISAF and to their National Anti-Doping Organizations, and shall cooperate with investigations conducted by any Anti-Doping Organization with authority to conduct the investigation.

21.16.4 All MNAs shall have disciplinary rules in place to prevent Athlete Support Personnel who are Using Prohibited Substances or Prohibited Methods without valid justification from providing support to Athletes under the jurisdiction of ISAF or the MNA.

21.16.5 All MNAs shall be required to conduct anti-doping education in coordination with their National Anti-Doping Organizations.

21.17 Stature of Limitations

No anti-doping rule violation proceeding may be commenced against an Athlete or other Person unless he or she has been notified of the anti-doping rule violation as provided in Regulation 21.7, or notification has been reasonably attempted, within ten years from the date the violation is asserted to have occurred.

21.18 ISAF Compliance Reports to WADA

ISAF will report to WADA on ISAF’s compliance with the Code in accordance with Article 23.5.2 of the Code.

21.19 Education
ISAF shall plan, implement, evaluate and monitor information, education and prevention programs for doping-free sport on at least the issues listed at Regulation 21.18.2 of the Code, and shall support active participation by Athletes and Athlete Support Personnel in such programs.

21.20 Amendment and Interpretation of Anti-Doping Rules

21.20.1 These Anti-Doping Rules may be amended from time to time by ISAF.

21.20.2 These Anti-Doping Rules shall be interpreted as an independent and autonomous text and not by reference to existing law or statutes.

21.20.3 The headings used for the various Parts and Regulations of these Anti-Doping Rules are for convenience only and shall not be deemed part of the substance of these Anti-Doping Rules or to affect in any way the language of the provisions to which they refer.

21.20.4 The Code and the International Standards shall be considered integral parts of these Anti-Doping Rules and shall prevail in case of conflict.

21.20.5 These Anti-Doping Rules have been adopted pursuant to the applicable provisions of the Code and shall be interpreted in a manner that is consistent with applicable provisions of the Code. The Introduction shall be considered an integral part of these Anti-Doping Rules.

21.20.6 The comments annotating various provisions of the Code and these Anti-Doping Rules shall be used to interpret these Anti-Doping Rules.

21.20.7 These Anti-Doping Rules have come into full force and effect on 1 January 2015 (the “Effective Date”). They shall not apply retroactively to matters pending before the Effective Date; provided, however, that:

(a) Anti-doping rule violations taking place prior to the Effective Date count as “first violations” or “second violations” for purposes of determining sanctions under Regulation 21.10 for violations taking place after the Effective Date.

(b) The retrospective periods in which prior violations can be considered for purposes of multiple violations under Regulation 21.10.7(e) and the statute of limitations set forth in Regulation 21.17 are procedural rules and should be applied retroactively; provided, however, that Regulation 21.17 shall only be applied retroactively if the statute of limitations period has not already expired by the Effective Date. Otherwise, with respect to any anti-doping rule violation case which is pending as of the Effective Date and any anti-doping rule violation case brought after the Effective Date based on an anti-doping rule violation which occurred prior to the Effective Date, the case shall be governed by the substantive anti-doping rules in effect at the time the alleged anti-doping rule violation occurred unless the panel hearing the case determines the principle of “lex mitior” appropriately applies under the circumstances of the case.

(c) Any Regulation 21.2.4 whereabouts failure (whether a Filing Failure or a Missed Test, as those terms are defined in the International Standard for Testing and Investigations) prior to the Effective Date shall be carried forward and may be relied
upon, prior to expiry, in accordance with the International Standard for Testing and Investigation, but it shall be deemed to have expired 12 months after it occurred.

(d) With respect to cases where a final decision finding an anti-doping rule violation has been rendered prior to the Effective Date, but the Athlete or other Person is still serving the period of Ineligibility as of the Effective Date, the Athlete or other Person may apply to the Anti-Doping Organization which had results management responsibility for the anti-doping rule violation to consider a reduction in the period of Ineligibility in light of these Anti-Doping Rules. Such application must be made before the period of Ineligibility has expired. The decision rendered may be appealed pursuant to Regulation 21.13.2. These Anti-Doping Rules shall have no application to any case where a final decision finding an anti-doping rule violation has been rendered and the period of Ineligibility has expired.

(e) For purposes of assessing the period of Ineligibility for a second violation under Regulation 21.10.7(a), where the sanction for the first violation was determined based on rules in force prior to the Effective Date, the period of Ineligibility which would have been assessed for that first violation had these Anti-Doping Rules been applicable, shall be applied.

21.21 Interpretation of the Code

21.21.1 The official text of the Code shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

21.21.2 The comments annotating various provisions of the Code shall be used to interpret the Code.

21.21.3 The Code shall be interpreted as an independent and autonomous text and not by reference to the existing law or statutes of the Signatories or governments.

21.21.4 The headings used for the various Parts and Regulations of the Code are for convenience only and shall not be deemed part of the substance of the Code or to affect in any way the language of the provisions to which they refer.

21.21.5 The Code shall not apply retroactively to matters pending before the date the Code is accepted by a Signatory and implemented in its rules. However, pre-Code anti-doping rule violations would continue to count as "first violations" or "second violations" for purposes of determining sanctions under Regulation 21.10 for subsequent post-Code violations.

21.21.6 The Purpose, Scope and Organization of the World Anti-Doping Program and the Code and Definitions, and Appendix 1, Examples of the Application of Regulation 21.10, shall be considered integral parts of the Code.

21.22 Additional Roles and Responsibilities of Athletes and Other Persons

21.22.1 Roles and Responsibilities of Athletes

It is the responsibility of Athletes:
(a) to be knowledgeable of and comply with these Anti-Doping Rules;

(b) to be available for Sample collection at all times;

(c) take responsibility, in the context of anti-doping, for what they ingest and Use;

(d) to inform medical personnel of their obligation not to Use Prohibited Substances and Prohibited Methods and to take responsibility to make sure that any medical treatment received does not violate these Anti-Doping Rules;

(e) to disclose to their National Anti-Doping Organization and to ISAF any decision by a non-Signatory finding that the Athlete committed an anti-doping rule violation within the previous ten years; and

(f) to cooperate with Anti-Doping Organizations investigating anti-doping rule violations.

(g) Failure by any Athlete to cooperate in full with ISAF, a MNA or Anti-Doping Organizations investigating anti-doping rule violations may result in a report being made under Racing Rule of Sailing 69 and the failure may regarded as gross misconduct under that rule.

21.22.2 Roles and Responsibilities of Athlete Support Personnel

It is the responsibility of Athletes Support Personnel:

(a) to be knowledgeable of and comply with these Anti-Doping Rules;

(b) to cooperate with the Athlete Testing program;

(c) to use his or her influence on Athlete values and behavior to foster anti-doping attitudes;

(d) to disclose to his or her National Anti-Doping Organization and to ISAF any decision by a non-Signatory finding that he or she committed an anti-doping rule violation within the previous ten years;

(e) to cooperate with Anti-Doping Organizations investigating anti-doping rule violations; and

(f) not to Use or Possess any Prohibited Substance or Prohibited Method without valid justification.

Failure by Athlete Support Personnel to cooperate in full with Anti-Doping Organizations investigating anti-doping rule violations, or Use or Possession of a Prohibited Substance or Prohibited Method by an Athlete Support Personnel without valid justification, may result in a report being made under Racing Rule of Sailing 69 and the conduct in question may be regarded as gross misconduct.
APPENDIX 1 EXAMPLES OF THE APPLICATION OF REGULATION 21.10

EXAMPLE 1.

Facts: An Adverse Analytical Finding results from the presence of an anabolic steroid in an In-Competition test (Regulation 21.2.1); the Athlete promptly admits the anti-doping rule violation; the Athlete establishes No Significant Fault or Negligence; and the Athlete provides Substantial Assistance.

Application of Consequences:

1. The starting point would be Regulation 21.10.2. Because the Athlete is deemed to have No Significant Fault that would be sufficient corroborating evidence (Regulations 21.10.2(a)(i) and 21.10(b)(iii)) that the anti-doping rule violation was not intentional, the period of Ineligibility would thus be two years, not four years (Regulation 21.10.2(b)).

2. In a second step, the panel would analyze whether the Fault-related reductions (Regulations 21.10.4 and 21.10.5) apply. Based on No Significant Fault or Negligence (Regulation 21.10.5(a)) since the anabolic steroid is not a Specified Substance, the applicable range of sanctions would be reduced to a range of two years to one year (minimum one-half of the two year sanction). The panel would then determine the applicable period of Ineligibility within this range based on the Athlete’s degree of Fault. (Assume for purposes of illustration in this example that the panel would otherwise impose a period of Ineligibility of 16 months.)

3. In a third step, the panel would assess the possibility for suspension or reduction under Regulation 21.10.6 (reductions not related to Fault). In this case, only Regulation 21.10.6(a) (Substantial Assistance) applies. (Regulation 21.10.6(c), Prompt Admission, is not applicable because the period of Ineligibility is already below the two-year minimum set forth in Regulation 21.10.6(c).) Based on Substantial Assistance, the period of Ineligibility could be suspended by three-quarters of 16 months.* The minimum period of Ineligibility would thus be four months. (Assume for purposes of illustration in this example that the panel suspends ten months and the period of Ineligibility would thus be six months.)

4. Under Regulation 21.10.11, the period of Ineligibility, in principle, starts on the date of the final hearing decision. However, because the Athlete promptly admitted the anti-doping rule violation, the period of Ineligibility could start as early as the date of Sample collection, but in any event the Athlete would have to serve at least one-half of the Ineligibility period (i.e., three months) after the date of the hearing decision (Regulation 21.10.11(b)).

5. Since the Adverse Analytical Finding was committed in a Competition, the panel would have to automatically Disqualify the result obtained in that Competition (Regulation 21.9).

6. According to Regulation 21.10.8, all results obtained by the Athlete subsequent to the date of the Sample collection until the start of the period of Ineligibility would also be Disqualified unless fairness requires otherwise.

7. The information referred to in Regulation 21.14.3(b) must be Publicly Disclosed, unless the Athlete is a Minor, since this is a mandatory part of each sanction (Regulation 21.10.13).
8. The *Athlete* is not allowed to participate in any capacity in a *Competition* or other sport-related activity under the authority of any *Signatory* or its affiliates during the *Athlete’s period of Ineligibility* (Regulation 21.10.12(a)). However, the *Athlete* may return to train with a team or to use the facilities of a club or other member organization of a *Signatory* or its affiliates during the shorter of: (a) the last two months of the *Athlete’s period of Ineligibility*, or (b) the last one-quarter of the period of *Ineligibility* imposed (Regulation 21.10.12(b)). Thus, the *Athlete* would be allowed to return to training one and one-half months before the end of the period of *Ineligibility*.

**EXAMPLE 2.**

**Facts:** An Adverse Analytical Finding results from the presence of a stimulant which is a *Specified Substance* in an *In-Competition* test (Regulation 21.2.1); the *Anti-Doping Organization* is able to establish that the *Athlete* committed the anti-doping rule violation intentionally; the *Athlete* is not able to establish that the *Prohibited Substance* was *Used Out-of-Competition* in a context unrelated to sport performance; the *Athlete* does not promptly admit the anti-doping rule violation as alleged; the *Athlete* does provide *Substantial Assistance*.

**Application of Consequences:**

1. The starting point would be Regulation 21.10.2. Because the *Anti-Doping Organization* can establish that the anti-doping rule violation was committed intentionally and the *Athlete* is unable to establish that the substance was permitted *Out-of-Competition* and the Use was unrelated to the *Athlete’s* sport performance (Regulation 21.10.2(c)), the period of *Ineligibility* would be four years (Regulation 21.10.2.(a)(ii)).

2. Because the violation was intentional, there is no room for a reduction based on *Fault* (no application of Regulations 21.10.4 and 21.10.5). Based on *Substantial Assistance*, the sanction could be suspended by up to three-quarters of the four years.* The minimum period of *Ineligibility* would thus be one year.

3. Under Regulation 21.10.11, the period of *Ineligibility* would start on the date of the final hearing decision.

4. Since the Adverse Analytical Finding was committed in a *Competition*, the panel would automatically *Disqualify* the result obtained in the *Competition*.

5. According to Regulation 21.10.8, all results obtained by the *Athlete* subsequent to the date of *Sample* collection until the start of the period of *Ineligibility* would also be *Disqualified* unless fairness requires otherwise.

6. The information referred to in Regulation 21.14.3(b) must be *Publicly Disclosed*, unless the *Athlete* is a *Minor*, since this is a mandatory part of each sanction (Regulation 21.10.13).

7. The *Athlete* is not allowed to participate in any capacity in a *Competition* or other sport-related activity under the authority of any *Signatory* or its affiliates during the *Athlete’s period of Ineligibility* (Regulation 21.10.12(a)). However, the *Athlete* may return to train with a team or to use the facilities of a club or other member organization of a *Signatory* or its affiliates during the shorter of: (a) the last two months of the *Athlete’s period of Ineligibility*, or (b) the last one-quarter of the period of *Ineligibility* imposed (Regulation 21.10.12(b)). Thus, the *Athlete* would be allowed to return to training one and one-half months before the end of the period of *Ineligibility*.  

---

* The minimum period of *Ineligibility* would thus be one year.
EXAMPLE 3.

**Facts:** An *Adverse Analytical Finding* results from the presence of an anabolic steroid in an *Out-of-Competition* test (Regulation 21.2.1); the *Athlete* establishes *No Significant Fault or Negligence*; the *Athlete* also establishes that the *Adverse Analytical Finding* was caused by a *Contaminated Product*.

**Application of Consequences:**

1. The starting point would be Regulation 21.10.2. Because the *Athlete* can establish through corroborating evidence that he did not commit the anti-doping rule violation intentionally, i.e., he had *No Significant Fault in Using a Contaminated Product* (Regulations 21.10.2(a)(i) and 21.10.2(c)), the period of *Ineligibility* would be two years (Regulations 21.10.2(b)).

2. In a second step, the panel would analyze the *Fault*-related possibilities for reductions (Regulations 21.10.4 and 21.10.5). Since the *Athlete* can establish that the anti-doping rule violation was caused by a *Contaminated Product* and that he acted with *No Significant Fault or Negligence* based on Regulation 21.10.5(a)(ii), the applicable range for the period of *Ineligibility* would be reduced to a range of two years to a reprimand. The panel would determine the period of *Ineligibility* within this range, based on the *Athlete*’s degree of *Fault*. (Assume for purposes of illustration in this example that the panel would otherwise impose a period of *Ineligibility* of four months.)

3. According to Regulation 21.10.8, all results obtained by the *Athlete* subsequent to the date of *Sample* collection until the start of the period of *Ineligibility* would be *Disqualified* unless fairness requires otherwise.

4. The information referred to in Regulation 21.14.3(b) must be *Publicly Disclosed*, unless the *Athlete* is a *Minor*, since this is a mandatory part of each sanction (Regulation 21.10.13).

5. The *Athlete* is not allowed to participate in any capacity in a *Competition* or other sport-related activity under the authority of any *Signatory* or its affiliates during the *Athlete*’s period of *Ineligibility* (Regulation 21.10.12(a)). However, the *Athlete* may return to train with a team or to use the facilities of a club or other member organization of a *Signatory* or its affiliates during the shorter of: (a) the last two months of the *Athlete*’s period of *Ineligibility*, or (b) the last one-quarter of the period of *Ineligibility* imposed (Regulation 21.10.12(b)). Thus, the *Athlete* would be allowed to return to training one month before the end of the period of *Ineligibility*.

EXAMPLE 4.

**Facts:** An *Athlete* who has never had an *Adverse Analytical Finding* or been confronted with an anti-doping rule violation spontaneously admits that she *Used* an anabolic steroid to enhance her performance. The *Athlete* also provides *Substantial Assistance*.

**Application of Consequences:**
1. Since the violation was intentional, Regulation 21.10.2(a) would be applicable and the basic period of Ineligibility imposed would be four years.

2. There is no room for Fault-related reductions of the period of Ineligibility (no application of Regulations 21.10.4 and 21.10.5).

3. Based on the Athlete’s spontaneous admission (Regulation 21.10.6(b)) alone, the period of Ineligibility could be reduced by up to one-half of the four years. Based on the Athlete’s Substantial Assistance (Regulation 21.10.6(a)) alone, the period of Ineligibility could be suspended up to three-quarters of the four years.* Under Regulation 21.10.6(d), in considering the spontaneous admission and Substantial Assistance together, the most the sanction could be reduced or suspended would be up to three-quarters of the four years. The minimum period of Ineligibility would be one year.

4. The period of Ineligibility, in principle, starts on the day of the final hearing decision (Regulation 21.10.11). If the spontaneous admission is factored into the reduction of the period of Ineligibility, an early start of the period of Ineligibility under Regulation 21.10.11(b) would not be permitted. The provision seeks to prevent an Athlete from benefitting twice from the same set of circumstances. However, if the period of Ineligibility was suspended solely on the basis of Substantial Assistance, Regulation 21.10.11(b) may still be applied, and the period of Ineligibility started as early as the Athlete’s last Use of the anabolic steroid.

5. According to Regulation 21.10.8, all results obtained by the Athlete subsequent to the date of the anti-doping rule violation until the start of the period of Ineligibility would be Disqualified unless fairness requires otherwise.

6. The information referred to in Regulation 21.14.3(b) must be Publicly Disclosed, unless the Athlete is a Minor, since this is a mandatory part of each sanction (Regulation 21.10.13).

7. The Athlete is not allowed to participate in any capacity in a Competition or other sport-related activity under the authority of any Signatory or its affiliates during the Athlete’s period of Ineligibility (Regulation 21.10.12(a)). However, the Athlete may return to train with a team or to use the facilities of a club or other member organization of a Signatory or its affiliates during the shorter of: (a) the last two months of the Athlete’s period of Ineligibility, or (b) the last one-quarter of the period of Ineligibility imposed (Regulation 21.10.12(b)). Thus, the Athlete would be allowed to return to training two months before the end of the period of Ineligibility.

EXAMPLE 5.

Facts:

An Athlete Support Person helps to circumvent a period of Ineligibility imposed on an Athlete by entering him into a Competition under a false name. The Athlete Support Person comes forward with this anti-doping rule violation (Regulation 21.2.9) spontaneously before being notified of an anti-doping rule violation by an Anti-Doping Organization.

Application of Consequences:
1. According to Regulation 21.10.3(d), the period of Ineligibility would be from two up to four years, depending on the seriousness of the violation. (Assume for purposes of illustration in this example that the panel would otherwise impose a period of Ineligibility of three years.)

2. There is no room for Fault-related reductions since intent is an element of the anti-doping rule violation in Regulation 21.2.9 (see comment to Regulation 21.10.5(b)).

3. According to Regulation 21.10.6(b), provided that the admission is the only reliable evidence, the period of Ineligibility may be reduced down to one-half. (Assume for purposes of illustration in this example that the panel would impose a period of Ineligibility of 18 months.)

4. The information referred to in Regulation 21.14.3(b) must be Publicly Disclosed unless the Athlete Support Person is a Minor, since this is a mandatory part of each sanction (Regulation 21.10.13).

EXAMPLE 6.

Facts: An Athlete was sanctioned for a first anti-doping rule violation with a period of Ineligibility of 14 months, of which four months were suspended because of Substantial Assistance. Now, the Athlete commits a second anti-doping rule violation resulting from the presence of a stimulant which is not a Specified Substance in an In-Competition test (Regulation 21.2.1); the Athlete establishes No Significant Fault or Negligence; and the Athlete provided Substantial Assistance. If this were a first violation, the panel would sanction the Athlete with a period of Ineligibility of 16 months and suspend six months for Substantial Assistance.

Application of Consequences:

1. Regulation 21.10.7 is applicable to the second anti-doping rule violation because Regulation 21.10.7(d)(i) and Regulation 21.10.7(e) apply.

2. Under Regulation 21.10.7(a), the period of Ineligibility would be the greater of:

(a) six months;
(b) one-half of the period of Ineligibility imposed for the first anti-doping rule violation without taking into account any reduction under Regulation 21.10.6 (in this example, that would equal one-half of 14 months, which is seven months); or
(c) twice the period of Ineligibility otherwise applicable to the second anti-doping rule violation treated as if it were a first violation, without taking into account any reduction under Regulation 21.10.6 (in this example, that would equal two times 16 months, which is 32 months).

Thus, the period of Ineligibility for the second violation would be the greater of (a), (b) and (c), which is a period of Ineligibility of 32 months.

3. In a next step, the panel would assess the possibility for suspension or reduction under Regulation 21.10.6 (non-Fault-related reductions). In the case of the second violation, only Regulation 21.10.6(a) (Substantial Assistance) applies. Based on Substantial Assistance, the period of Ineligibility could be suspended by three-quarters of 32 months.* The minimum period of Ineligibility would thus be eight months. (Assume for purposes of illustration in this example...
that the panel suspends eight months of the period of Ineligibility for Substantial Assistance, thus reducing the period of Ineligibility imposed to two years.)

4. Since the Adverse Analytical Finding was committed in a Competition, the panel would automatically Disqualify the result obtained in the Competition.

5. According to Regulation 21.10.8, all results obtained by the Athlete subsequent to the date of Sample collection until the start of the period of Ineligibility would also be Disqualified unless fairness requires otherwise.

6. The information referred to in Regulation 21.14.3(b) must be Publicly Disclosed, unless the Athlete is a Minor, since this is a mandatory part of each sanction (Regulation 21.10.13).

7. The Athlete is not allowed to participate in any capacity in a Competition or other sport-related activity under the authority of any Signatory or its affiliates during the Athlete’s period of Ineligibility (Regulation 21.10.12(a)). However, the Athlete may return to train with a team or to use the facilities of a club or other member organization of a Signatory or its affiliates during the shorter of: (a) the last two months of the Athlete’s period of Ineligibility, or (b) the last one-quarter of the period of Ineligibility imposed (Regulation 21.10.12(b)). Thus, the Athlete would be allowed to return to training two months before the end of the period of Ineligibility.

* Upon the approval of WADA in exceptional circumstances, the maximum suspension of the period of Ineligibility for Substantial Assistance may be greater than three-quarters, and reporting and publication may be delayed.
APPENDIX 2  Consent Form

As a member of [MNA] and/or a participant in an event authorized or recognized by [MNA or International Federation], I hereby declare as follows:

I acknowledge that I am bound by, and confirm that I shall comply with, all of the provisions of ISAF Anti-Doping Rules (as contained in ISAF Regulation 21, as amended from time to time) and the International Standards issued by the World Anti-Doping Agency and published on its website.

I acknowledge the authority of ISAF [and its member MNAs and/or National Anti-Doping Organizations] under the ISAF Anti-Doping Rules to enforce, to manage results under, and to impose sanctions in accordance with, the ISAF Anti-Doping Rules.

I acknowledge and agree that any dispute arising out of a decision made pursuant to the ISAF Anti-Doping Rules, after exhaustion of the process expressly provided for in the ISAF Anti-Doping Rules, may be appealed exclusively as provided in Regulation 21.13 of the ISAF Anti-Doping Rules to an appellate body for final and binding arbitration, which in the case of International-Level Athletes is the Court of Arbitration for Sport (CAS).

I acknowledge and agree that the decisions of the arbitral appellate body referenced above shall be final and enforceable, and that I will not bring any claim, arbitration, lawsuit or litigation in any other court or tribunal.

I have read and understand the present declaration.

Date ____________________________  Print Name (Last Name, First Name)

Date of Birth ____________________________  Signature (or, if a minor, signature of legal guardian)

(Day/Month/Year)
APPENDIX 3 Testing

1. Validation of the Identity of Athletes

The Sample Collection Authority appointed by ISAF will validate the identity of an Athlete selected to provide a sample by their Event accreditation which includes a photograph, or by their passport.

2. Delayed Reporting

The DCO / Chaperone may at his / her discretion consider any reasonable third party request or any request by the Athlete for permission to delay reporting to the Doping Control Station following acknowledgement and acceptance of notification, and / or to leave the Doping Control Station temporarily after arrival, and may grant such permission if the Athlete can be continuously chaperoned and kept under direct observation during the delay. For example, delayed reporting to / temporary departure from the Doping Control Station may be permitted for the following activities:

a. For In-Competition Testing:
   i. The washing down of equipment and making safe;
   ii. Participation in a presentation ceremony;
   iii. Fulfillment of media commitments;
   iv. Obtaining necessary medical treatment;
   v. Locating a representative and / or interpreter;
   vi. Obtaining photo identification; or
   vii. Any other reasonable circumstances, as determined by the DCO, taking into account any instructions of the Testing Authority.

b. For Out-of-Competition Testing:
   i. Locating a representative;
   ii. Completing a training session;
   iii. Receiving necessary medical treatment;
   iv. Obtaining photo identification; or
   v. Any other reasonable circumstances, as determined by the DCO, taking into account any instructions of the Testing Authority.

3. Who May be Present During the Sample Collection Session

In addition to the Sample Collection Personnel the following people may be present during the Sample Collection Session.

a. A representative and / or interpreter; except when the Athlete is passing a urine sample;

b. A Minor may choose to be accompanied by a representative throughout the entire Sample Collection Session. The representative shall not witness the passing of a urine Sample unless requested to do so by the Minor. Even if the Minor declines a representative, the Sample Collection Authority, DCO or Chaperone shall consider
whether another third party ought to be present during notification and / or collection of the Sample from the Athlete.

c. An Athlete with an intellectual, physical or sensorial impairment may be assisted by the Athlete’s representative or Sample collection personnel during the Sample Collection process where authorized by the Athlete and agreed to by the DCO.

d. A WADA observer where applicable under the Independent Observer Program. The WADA observer shall not directly observe the passing of a urine Sample.

4. Storage of Sample Collected

To ensure the integrity, identity and security of each Sample collected prior to transport from the Doping Control Station:

a. Samples must not be left unattended, unless they are locked away in a refrigerator or cupboard, for example. Access shall be restricted to authorized personnel.

b. Where possible, Samples should be stored in a cool environment. Warm conditions should be avoided.

c. The DCO shall accurately complete appropriate documentation for each transport bag / container to ensure that the laboratory can verify the contents of the bag / container.

d. The DCO shall follow the ADO’s system to ensure that, where required, instructions for the type of analysis to be conducted are provided to the laboratory.

e. The DCO shall complete the Chain of Custody form. The laboratory copy of this form(s) and the laboratory copy of the Doping Control form should be placed in the transport bag with the Samples. Documentation identifying the Athlete shall not be included with the Samples.

f. The DCO shall keep the Samples secured and under his or her control until they are passed to the courier.

Current Position

Current Regulation 21.

Reason

The new Code comes into effect 1 January 2015 and in order to be deemed compliant by WADA ISAF must amend its rules and policies to include the mandatory articles and principles of the Code.